EP2334802A1 - Procédés de génération de bibliothèques spécifiques de gènes - Google Patents

Procédés de génération de bibliothèques spécifiques de gènes

Info

Publication number
EP2334802A1
EP2334802A1 EP09813548A EP09813548A EP2334802A1 EP 2334802 A1 EP2334802 A1 EP 2334802A1 EP 09813548 A EP09813548 A EP 09813548A EP 09813548 A EP09813548 A EP 09813548A EP 2334802 A1 EP2334802 A1 EP 2334802A1
Authority
EP
European Patent Office
Prior art keywords
capture
target
binding region
library
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09813548A
Other languages
German (de)
English (en)
Other versions
EP2334802A4 (fr
Inventor
Christopher K. Raymond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Publication of EP2334802A1 publication Critical patent/EP2334802A1/fr
Publication of EP2334802A4 publication Critical patent/EP2334802A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Definitions

  • DNA deoxyribonucleic acid
  • pharmacogenomics challenge is to comprehensively identify the genes and functional polymorphisms associated with the variability in drug response. Screens for numerous genetic markers performed for populations large enough to yield statistically significant data are needed before associations can be made between a given genotype and a particular disease.
  • the study of complex genomes and, in particular, the search for the genetic basis of disease in humans, requires genotyping on a massive scale, which is demanding in terms of cost, time, and labor. Such costly demands are even greater when the methodology employed involves serial analysis of individual DNA samples, i.e., separate reactions for individual samples.
  • the present invention provides a method of generating a population of DNA molecules, each DNA molecule comprising a nucleic acid insert region flanked by a first primer binding region and a second primer binding region, the method comprising (a) fragmenting a starting population of DNA molecules into a population of fragmented insert DNA molecules; (b) combining in a ligation reaction, the population of fragmented insert DNA molecules of step (a) with (i) a plurality of first stem-loop linker oligonucleotides comprising a sequence that is complementary to a first primer binding region, and (ii) a plurality of second stem-loop linker oligonucleotides comprising a sequence that is complementary to a second primer binding region; (c)
  • the present invention provides a method of enriching a library for target nucleic acid regions of interest.
  • the method according to this aspect of the invention comprises (a) contacting a library of DNA molecules comprising a subpopulation of nucleic acid target insert sequences of interest flanked by a first primer binding region and a second primer binding region within a larger population of nucleic acid insert sequences flanked by the first primer binding region and the second primer binding region with a set of capture probes, the set of capture probes comprising a plurality of capture oligonucleotides, each comprising a first target sequence-specific binding region and a second capture reagent binding region, under conditions that allow binding between the capture oligonucleotides and the nucleic acid target regions of interest, to form a plurality of complexes between target regions of interest and capture probes; (b) contacting the mixture of step (a) with a capture reagent and separating the capture reagent bound complex from the mixture; and (c) eluting the
  • the method further comprises amplifying the eluted target regions of interest flanked by the first primer binding region and the second primer binding region with a forward PCR primer and a reverse PCR primer that bind to the first and second primer binding regions to generate a library that is enriched for target regions of interest.
  • the invention provides a method of generating a target enriched, sequencing ready library for resequencing at least one target region of interest from a nucleic acid containing sample.
  • the method according to this aspect of the invention comprises (a) providing a library comprising fragmented nucleic acid molecules flanked by a first primer binding region and a second primer binding region; and (b) enriching the library for target sequences with a set of capture probes comprising a plurality of capture oligonucleotides, each comprising a first target-specific binding region and a second capture reagent binding region, thereby generating an enriched sequencing ready library for resequencing at least one target region of interest.
  • the methods of the invention can be used to create populations of nucleic acid molecules (also referred to in the art as "libraries" of nucleic acid molecules) useful for a variety of purposes, such as resequencing a target region of interest.
  • FIGURE 1 illustrates an embodiment of a method for generating a population of DNA molecules comprising a nucleic acid insert region flanked by a first primer binding region and a second primer binding region, as described in Example 1 ;
  • FIGURE 2A shows the densities for groups of bar codes (rows) for each amplicon of five genes (columns), demonstrating that the bar-coded population of DNA molecules comprising a nucleic acid insert region flanked by a first primer binding region and a second primer binding region generated sequence that was equivalent to non-bar-coded population of DNA molecules, as described in Example 1;
  • FIGURE 2B shows both the expected and observed distribution of sequencing reads, demonstrating the accurate association of bar-coded sequence results with the correct samples in accordance with an embodiment of a method for generating a population of DNA molecules comprising a nucleic acid insert region flanked by a first primer binding region and a second primer binding region, as described in Example 1 ;
  • FIGURE 3 is a flowchart showing the steps of a method of generating a sequence ready library from a starting population of DNA molecules, with the optional steps of enrichment of the library for target sequences using solution-based capture methods, in accordance with various embodiments of the methods of the invention;
  • FIGURE 4 illustrates an embodiment of a method for enriching a population of
  • DNA molecules comprising a nucleic acid insert region flanked by a first primer binding region and a second primer binding region for target regions of interest using capture probes comprising a capture binding region that directly binds to a capture reagent, as described in Example 3;
  • FIGURE 5 illustrates an embodiment of a method for enriching a population of DNA molecules for target regions of interest using capture probes comprising a capture binding region that indirectly binds to a capture reagent, as described in Example 4;
  • FIGURE 6 is a flow chart of the steps of solution-based capture in accordance with various embodiments of the methods of the invention.
  • FIGURE 7 illustrates the sequencing read depth for the exons in the exemplary gene target PIK3CA obtained from a library that was enriched using indirect solution capture with capture oligos that were complementary to these exons, demonstrating high read densities (e.g., 1,000 reads) along all of the targeted exons, as described in Example 4;
  • FIGURE 8 illustrates the sequencing read depth for the exons in the exemplary gene target AKT 1 gene in a 77-gene experiment, as described in Example 5;
  • FIGURE 9 graphically illustrates the percent of target bases sequenced at a specific sequencing read depth from a library that was enriched with three rounds of solution-based capture in accordance with an embodiment of the methods of the invention, as described in Example 5;
  • FIGURE 1OA illustrates a read density map for determining the copy number variation of a region on a chromosome from sequence analysis of a sequence ready library generated according to an embodiment of a method of the invention, as described in Example 6;
  • FIGURE 1OB shows the results of an experiment carried out to measure the copy number variation from a region of chromosome 14 in a normal human subject using the sequence ready library generated according to an embodiment of a method of the invention, as described in Example 6;
  • FIGURE 1 IA shows the results of transcriptional analysis of a cardiovascular risk locus on a 1500 Kb region of chromosome 9p21 containing two identified SNPs, (SNPA and SNPB) showing plus strand transcription that includes the associated SNPA and SNPB appears to span approximately 800 Kb, with the arrows showing potential transcription units, as described in Example 7; and
  • FIGURE HB shows the generation of a sequencing-ready library generated from not-so-random primer amplified from the whole transcriptome and enriched for the risk associated locus encompassing SNPA and SNPB shown in FIGURE HA with capture probes (arrows), as described in Example 7.
  • the use of the term “about” in the context of the present invention is to connote inherent problems with precise measurement of a specific element, characteristic, or other trait.
  • the term “about,” as used herein in the context of the claimed invention simply refers to an amount or measurement that takes into account single or collective calibration and other standardized errors generally associated with determining that amount or measurement.
  • a concentration of "about” 100 mM of Tris can encompass an amount of 100 mM ⁇ .5 mM, if .5 mM represents the collective error bars in arriving at that concentration.
  • any measurement or amount referred to in this application can be used with the term “about” if that measurement or amount is susceptible to errors associated with calibration or measuring equipment, such as a scale, pipetteman, pipette, graduated cylinder, etc.
  • nucleic acid molecule encompasses both deoxyribonucleotides and ribonucleotides and refers to a polymeric form of nucleotides including two or more nucleotide monomers.
  • the nucleotides can be naturally occurring, artificial, and/or modified nucleotides.
  • an "isolated nucleic acid” is a nucleic acid molecule that exists in a physical form that is non-identical to any nucleic acid molecule of identical sequence as found in nature; “isolated” does not require, although it does not prohibit, that the nucleic acid so described has itself been physically removed from its native environment.
  • a nucleic acid can be said to be “isolated” when it includes nucleotides and/or internucleoside bonds not found in nature.
  • nucleic acid When instead composed of natural nucleosides in phosphodiester linkage, a nucleic acid can be said to be "isolated” when it exists at a purity not found in nature, where purity can be adjudged with respect to the presence of nucleic acids of other sequences, with respect to the presence of proteins, with respect to the presence of lipids, or with respect to the presence of any other component of a biological cell, or when the nucleic acid lacks sequence that flanks an otherwise identical sequence in an organism's genome, or when the nucleic acid possesses sequence not identically present in nature.
  • isolated nucleic acid includes nucleic acids integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant vectors present as episomes, or as integrated into a host cell chromosome.
  • subject refers to an organism or to a cell sample, tissue sample, or organ sample derived therefrom, including, for example, cultured cell lines, biopsy, blood sample, or fluid sample containing a cell.
  • an organism may be an animal, including but not limited to, an animal such as a cow, a pig, a mouse, a rat, a chicken, a cat, a dog, etc., and is usually a mammal, such as a human.
  • the term “specifically bind” refers to two components (e.g., target-specific binding region and target) that are bound (e.g., hybridized, annealed, complexed) to one another sufficiently that the intended capture and enrichment steps can be conducted.
  • the term “specific” refers to the selective binding of two components (e.g., target-specific binding region and target) and not generally to other components unintended for binding to the subject components.
  • high stringency hybridization conditions means any condition in which hybridization will occur when there is at least 95%, preferably about 97% to 100%, nucleotide complementarity (identity) between the nucleic acid sequences of the nucleic acid molecule and its binding partner.
  • the hybridization conditions may be "medium stringency hybridization,” which can be selected that require less complementarity, such as from about 50% to about 90%, (e.g., 60%, 70%, 80%, 85%).
  • the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm of Karlin and Altschul ⁇ Proc. Natl. Acad. Sci.
  • the term "complementary” refers to nucleic acid sequences that are capable of base-pairing according to the standard Watson-Crick complementary rules. That is, the larger purines will base pair with the smaller pyrimidines to form combinations of guanine paired with cytosine (G: C) and adenine paired with either thymine (A: T) in the case of DNA, or adenine paired with uracil (A:U) in the case of RNA.
  • target refers to a nucleic acid molecule or polynucleotide whose presence and/or amount and/or sequence is desired to be determined and that has an affinity for a given target capture probe.
  • targets include regions of genomic DNA, PCR amplified products derived from RNA or DNA, DNA derived from RNA or DNA, ESTs, cDNA, and mutations, variants, or modifications thereof.
  • resequencing refers to a technique that determines the sequence of a genome of an organism using a reference sequence that has already been determined. It should be understood that resequencing may be performed on both the entire genome/transcriptome of an organism or a portion of the genome/transcriptome large enough to include the genetic change of the organism as a result of selection. Resequencing may be carried out using various sequencing methods, such as any sequencing platform amenable to producing DNA sequencing reads that can be aligned back to a reference genome, and is typically based on highly parallel technologies such as, for example, dideoxy "Sanger” sequencing, pyrosequencing on beads (e.g.. as described in U.S. Patent No.
  • the invention provides a method of generating a population of DNA molecules (i.e., a library) that may be used for resequencing analysis.
  • Each DNA molecule in the population of DNA molecules comprises a nucleic acid insert region flanked by a first primer binding region and a second primer binding region.
  • the method comprises (a) fragmenting a starting population of DNA molecules into a population of fragmented insert DNA molecules; and (b) combining in a ligation reaction, the population of fragmented insert DNA molecules of step (a) with (i) a plurality of first stem-loop linker oligonucleotides comprising a sequence that is complementary to a first primer binding region, and (ii) a plurality of second stem-loop linker oligonucleotides comprising a sequence that is complementary to a second primer binding region; (c) contacting the ligation reaction of step (b) with a polymerase under conditions suitable to synthesize the complementary strands corresponding to the first and second stem-loop linkers, thereby generating a plurality of double-stranded DNA molecules, each DNA molecule comprising an insert region flanked by a
  • FIGURE l, step D illustrates exemplary DNA molecules 5OA, 5OB generated according to the methods of this aspect of the invention comprising an insert fragment 10 flanked by a first stem-loop linker oligonucleotide 20 and a second stem-loop linker oligonucleotide 30.
  • FIGURE 3 illustrates an exemplary embodiment of the method of generating a sequencing-ready library 600 comprising a plurality of DNA molecules 5OA, 50B according to this aspect of the invention.
  • a starting population of DNA molecules containing one or more target sequence(s) of interest is fragmented.
  • a plurality of first stem-loop linker oligonucleotides, each comprising a sequence that is complementary to a first primer binding region, and a plurality of second stem-loop linker oligonucleotides, each comprising a sequence that is complementary to a second primer binding region are ligated to the ends of the DNA fragments (inserts).
  • the ligation mixture is filled in and PCR amplified with primers that bind to the first and second primer binding regions to generate a population of double-stranded DNA molecules, each DNA molecule comprising an insert region flanked by a first primer binding region and a second primer binding region (i.e., a library).
  • the library can be optionally sequenced or may be enriched for the target sequences of interest according to steps 650-670 shown in FIGURE 3, FIGURE 6, and further described herein. STARTING POPULATIONS OF NUCLEIC ACID MOLECULES
  • Examples of starting populations of nucleic acid molecules containing one or more target sequence(s) of interest for use in the methods of this aspect of the invention include genomic DNA, mRNA, tRNA, rRNA, cRNA, oligonucleotides, DNA derived from RNA or DNA, ESTs, cDNA, cDNA generated from not-so-random primed total RNA (e.g., as described in Example 7), PCR amplified products derived from RNA or DNA, microRNA, shRNA, siRNA, and mutations, variants, or modifications thereof.
  • the starting nucleic acid molecules may be isolated from a subject, such as a cell sample, tissue sample, or organ sample derived therefrom, including, for example, cultured cell lines, biopsy, blood sample, or fluid sample containing a cell.
  • the subject may be an animal, including but not limited to, an animal such as a cow, a pig, a mouse, a rat, a chicken, a cat, a dog, etc., and is usually a mammal, such as a human.
  • target nucleotide refers to a nucleic acid molecule or polynucleotide in a starting population of nucleic acid molecules having a target sequence whose presence and/or amount and/or nucleotide sequence is desired to be determined and that has an affinity for a given target capture probe.
  • target sequence refers generally to a nucleic acid sequence on a single strand of nucleic acid.
  • the target sequence may be a portion of a gene, a regulatory sequence, genomic DNA, cDNA, RNA including mRNA and rRNA, or others.
  • the target sequence may be a target sequence from a sample or a secondary target such as a product of an amplification reaction.
  • the starting population of nucleic acid molecules comprises PCR products amplified from a plurality of target-specific amplicons from a nucleic acid containing sample, as described in Example 1.
  • the starting population of nucleic acid molecules comprises total genomic DNA, as described in Example 2.
  • the starting population of nucleic acid molecules represents the whole transcriptome, as described in Example 7.
  • fragments are generated from at least about 1 genome-equivalent of starting DNA, such as at least about 10 genome-equivalents of DNA, such as at least about 100 genome-equivalents of DNA, such as at least about 1,000 genome-equivalents of DNA, such as at least about 10,000 genome-equivalents of DNA, such as at least about 100,000 genome-equivalents of DNA, such as at least about 300,000 genome-equivalents of DNA.
  • This fragmentation may be accomplished by methods known in the art, including chemical, enzymatic, and mechanical fragmentation.
  • the fragments are from about 10 to about 10,000 nucleotides in length.
  • the fragments are from about 50 to about 2,000 nucleotides in length.
  • the fragments are from about 10-1,000, 10-800, 10-500, 50-500, 50-250, 50-150 nucleotides in length.
  • the fragments are less than 500 nucleotides in length, such as less than 400 nucleotides, less than 300 nucleotides, less than 200 nucleotides, or less than 150 nucleotides in length.
  • the fragmentation is accomplished mechanically through the use of sonication.
  • the fragmentation is accomplished by digestion with DNase I, which induces random double-stranded breaks in DNA in the absence of Mg ++ and in the presence of Mn ++ , as described in Example 1.
  • the method may include the step of size selecting the fragments via standard methods such as column purification or isolation from an agarose gel.
  • the fragmented DNA molecules are blunt-end polished prior to ligation to the stem-loop linkers.
  • the blunt-end polishing step may be accomplished by incubation with a suitable enzyme, such as T4 polymerase (which has both 3' to 5' exonuclease activity and 5' to 3' polymerase activity).
  • T4 polymerase which has both 3' to 5' exonuclease activity and 5' to 3' polymerase activity.
  • the fragmented DNA molecules may be optionally phosphorylated, for example, using T4 polynucleotide kinase, prior to ligation to the stem-loop linkers.
  • the first stem-loop linker oligonucleotide 20 comprises a 5' region 24 with a sequence that is complementary to a sequence located in the 3' region 28 that forms a stem structure, and an intervening region 26 between the 5' and 3' region that forms a loop structure. Also located in the first stem-loop linker oligonucleotide 20 is a sequence 22 that is complementary to a first primer binding region 82 that may be positioned in the intervening region 26 or in the stem region.
  • the 5' region 24 and 3' region 28 hybridize together, resulting in the stem-loop linker oligonucleotide 20 structure with a double-stranded stem 24 and 28 with an intervening region 26 that forms a loop structure.
  • the second stem-loop linker oligonucleotide 30 comprises a 5' region 34 having a sequence that is complementary to a sequence located in the 3' region 38 that forms a stem structure, and an intervening region 36 between the 5' and 3' region that forms a loop structure. Also located in the second stem-loop linker oligonucleotide 30 is a sequence 32 that is complementary to a second primer binding region 92 that may be positioned in the intervening region 36 or in the stem region.
  • the 5' region 34 and 3' region 38 hybridize together, resulting in the stem-loop linker oligonucleotide 30 structure with a double-stranded stem 34 and 38 with an intervening region 36 that forms a loop structure.
  • each stem-loop linker 20, 30 is typically at least 40 nucleotides, such as at least 45 nucleotides, at least 50 nucleotides, at least 55 nucleotides, at least 60 nucleotides, at least 65 nucleotides, at least 70 nucleotides, up to a maximum length of about 200 nucleotides.
  • the stem-loop linkers are each from about 45 nucleotides to about 70 nucleotides in length.
  • the 5' complementary region 24 and the 3' complementary region 28 in the first stem-loop linker 20, and the 5' complementary regions 34 and the 3' complementary region 38 in the second stem-loop linker 30, can be from about 5 nucleotides to 100 nucleotide or greater, such as 10 nucleotides, 15 nucleotides, 20 nucleotides or more in length, and may be designed using a variety of different sequences that result in hybridization between the complementary regions on each stem-loop linker, resulting in a local region of double-stranded DNA (i.e., a stem).
  • stem sequences may be utilized that are from 15 to 18 nucleotides in length with equal representation of G:C and A:T base pairs. Such stem sequences are predicted to form stable dsDNA structures below their predicted melting temperatures of ⁇ 45°C.
  • the intervening loop regions 26, 36 in the first and second stem-loop linkers can be from about 10 nucleotides in length, 20 nucleotides, 30 nucleotides, 40 nucleotides or more in length.
  • the intervening loop region 26, 36 includes a nucleic acid sequence 22, 32 ranging in size from about 10 nucleotides to about 30 nucleotides that is complementary to a first and second PCR primer binding sequences 82, 92.
  • the regions complementary to a first and second primer binding sequence may be contained within any other part of the stem-loop linker.
  • the first 82 and second 92 PCR primer binding regions contain sequences that are distinct from one another and designed for providing a universal first primer binding site and a universal second primer binding site in the plurality of DNA molecules in a sequence-ready library, for binding to a first and second PCR primer to enable PCR amplification of an intervening insert sequence.
  • the stem-loop linker oligonucleotides further comprise one or more additional features such as a restriction enzyme site and/or an anchor probe binding site for attachment to a sequencing platform, such as a flow cell for massive parallel sequencing (e.g., Illumina, Inc.).
  • a sequencing platform such as a flow cell for massive parallel sequencing (e.g., Illumina, Inc.).
  • Illumina Genome Analyzer System is based on technology described in WO 98/44151, hereby incorporated by reference, wherein DNA molecules are bound to a sequencing platform (flow cell) via an anchor probe binding site (otherwise referred to as a flow cell binding site) and amplified in situ on a glass slide. The DNA molecules are then annealed to a sequencing primer and sequenced in parallel base-by-base using a reversible terminator approach.
  • the Illumina Genome Analyzer System utilizes flow-cells with 8 channels, generating sequencing reads of 18 to 36 bases in length, generating >1.3 Gbp of high quality data
  • the first 20 and second 30 stem-loop linkers each contains an anchor probe binding site for binding to a sequencing platform (e.g., a flow cell as described above).
  • the first 82 and second 92 PCR primer binding sites comprise a sequence that is also used as an anchor probe binding site for binding to a sequencing platform.
  • at least one of the first 20 or second 30 stem-loop linker oligonucleotides further comprises a sequence for annealing to a sequencing primer.
  • the first 20 stem-loop linker oligonucleotide comprises a sequence for annealing to a sequencing primer.
  • At least one of the stem-loop linker oligonucleotides further comprises one or more molecular bar code sequences (e.g., a nucleotide tag with a length of 1, 2, 3, 4 or more nucleotides) that can be utilized to identify the origin of insert sequences 10 in mixtures of bar-coded samples.
  • the molecular bar code sequences are used to create groups of polynucleotides that share a common feature. For example, such features can include the source/sample of origin, the processing conditions used to generate the polynucleotide, etc., as further described in Example 1.
  • the double-stranded nucleic acid fragments 10 are combined with the first 20 and second 30 stem-loop linker oligonucleotides in a ligation reaction with a suitable enzyme, such as T4 DNA ligase.
  • a suitable enzyme such as T4 DNA ligase.
  • the stem region of each stem-loop linker 20, 30 forms a blunt-ended, double-stranded DNA segment suitable for ligation to the blunt-ended, double-stranded nucleic acid fragments 10, resulting in a ligated structure having the 3' end of a stem-loop linker 20 or 30 covalently joined to the 5' end of the double-stranded DNA insert 10.
  • a pre-PCR fill-in reaction with a suitable polymerase such as Taq polymerase, is used to copy the sequence information from the ligated insert: stem-loop linker to the complementary strand, resulting in the fill-in ligation products shown in FIGURE 1, step C.
  • Step C the ligation reaction results in a mixture of ligation products including the target ligation products comprising inserts 10 flanked on each end by a pair of heterogeneous stem-loop linkers 20, 30 in a first orientation 50A and a second orientation 5OB, as well as ligation byproducts comprising inserts 10 flanked on each end by a pair of homogenous stem-loop linkers 20, 20 shown as ligation byproducts 60 or 30, 30, shown as ligation byproducts 70.
  • the initial population of ligation products includes a mixture of inserts flanked by heterogeneous linker ends 50A, 50B and inserts flanked by homogenous linker ends 60, 70.
  • a phenomenon referred to as suppression PCR is used to selectively enrich for the inserts flanked by heterogeneous linker ends 50A, 5OB.
  • suppression PCR P.D. Siebert et al., Nucleic Acids Res. 23:1087-1088 (1995)
  • it is difficult to amplify an extended stem-loop structure e.g., greater than 40 nucleotides because the double-stranded stem occludes the binding of PCR primers.
  • Step D the unwanted ligation byproducts 60, 70 are refractive to PCR amplification because the first stem-loop linker oligonucleotide and second stem-loop linker oligonucleotide are greater than 40 nucleotides.
  • step 630 the ligation mixture is amplified in a polymerase chain reaction (PCR) with a first PCR primer 52 that hybridizes to the first PCR primer binding site 82 and a second PCR primer 54 that hybridizes to the second PCR primer binding site 92 to generate a sequencing-ready library comprising a plurality of nucleic acid molecules 5OA, 50B containing a plurality of inserts that are derived from the starting population of DNA molecules (as shown in FIGURE 1, step D "PCR Products").
  • PCR polymerase chain reaction
  • PCR is a technique that is well known and involves the use of primer extension combined with thermal cycling to amplify a target sequence.
  • a desirable number of amplification cycles for use in the suppression PCR amplification (see FIGURE 3) step 630 is from 2 to 60 cycles, such as from 10 to 30 cycles, such as about 20 cycles.
  • the resulting amplification product comprises a library of a plurality of double-stranded nucleic acid molecules 50A, 50B, each comprising a nucleic acid insert region flanked by a first primer binding region and a second primer binding region.
  • the plurality of nucleic acid insert regions in the library includes one or more target sequences and can include enough different nucleic acid sequences to cover (i.e., represent) part or all of a source nucleic acid including, without limitation, a genome of an organism, a genomic locus, a cDNA library, a whole transcriptome of an organism, and the like.
  • such a library of double-stranded nucleic acid molecules may cover at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or at least about 95% up to about 100% of the source nucleic acid.
  • Such libraries generated according to the methods of the invention may be applied directly to a flow cell sequencing platform, such as an Illumina Genome Analyzer, for sequence analysis or sequenced using other standard methods and are therefore referred to as "sequencing-ready" libraries.
  • the methods of the invention are used to generate a sequencing-ready library for sequence analysis using the Illumina Genome Analyzer System and at least one of the linkers 20, 30 includes at least one anchor probe binding site (otherwise referred to as a flow cell binding site) and a sequence for annealing to a sequencing primer.
  • the library Prior to sequence analysis, the library is denatured (i.e., in 0.2 M NaOH) for 5 minutes at room temperature) and bound to the flow cell.
  • sequence-ready libraries can be analyzed separately or, if modified to contain molecular bar codes, a plurality of libraries can be combined as a mixture into a single pool of libraries and analyzed. When a reaction is performed on a pooled bar-coded library, the reaction need only be performed once.
  • the analysis can include detection (such as sequencing) of the molecular bar codes.
  • a library or pool of libraries made according to the methods of the invention can be sequenced at step 640 or may be further enriched for target sequences of interest (as shown in FIGURE 3, steps 650-670) using solution-based capture methods and analyzed as described in detail below.
  • the present invention provides a method of enriching a library for target nucleic acid regions of interest.
  • the method according to this aspect of the invention comprises (a) contacting a library of DNA molecules comprising a subpopulation of nucleic acid target insert sequences of interest flanked by a first primer binding region and a second primer binding region within a larger population of nucleic acid insert sequences flanked by the first primer binding region and the second primer binding region with a set of capture probes, the set of capture probes comprising a plurality of capture oligonucleotides, each comprising a first target sequence-specific binding region and a second capture reagent binding region, under conditions that allow binding between the capture oligonucleotides and the nucleic acid target regions of interest, to form a plurality of complexes between target regions of interest and capture probes; (b) contacting the mixture of step (a) with a capture reagent and separating the capture reagent bound complex from the mixture; and (c) eluting the
  • Any library of DNA molecules comprising a subpopulation of nucleic acid target insert sequences of interest flanked by a first primer binding region and a second primer binding region within a larger population of nucleic acid insert sequences flanked by the first primer binding region and the second primer binding region may be enriched for target sequences using the methods of this aspect of the invention.
  • a library of DNA molecules comprising a subpopulation of nucleic acid target insert sequences of interest flanked by a first primer binding region and a second primer binding region within a larger population of nucleic acid insert sequences flanked by the first primer binding region and the second primer binding region, generated using the methods of the invention, as shown in FIGURE 3 (steps 610-630) and described, supra, is enriched using the methods of this aspect of the invention.
  • the use of solution-based capture to enrich a library allows for the efficient creation of resequencing samples (sequence-ready libraries) that are largely composed of target sequences, as demonstrated in Examples 3-7.
  • the sense 100 or antisense 100' target capture probes each comprises a target sequence-specific binding region 102, 102' and a capture reagent binding region 104 attached to a moiety 110 for binding to a capture reagent 400.
  • step B the target-specific binding region 102 of sense 100 or antisense 100' target capture probes bind to a complementary or substantially complementary nucleic acid sequence contained in an insert region 10 or 10' of a nucleic acid molecule 50 in the library.
  • the moiety 110 (e.g., biotin) attached to the capture probe 100, 100' is then contacted with a capture reagent 400 (e.g., a magnetic bead) having a binding region 410 (e.g., streptavidin coating) and the complex is pulled out of solution with a sorting device 500 (e.g., a magnet) that binds to the capture reagent 400.
  • a capture reagent 400 e.g., a magnetic bead
  • a binding region 410 e.g., streptavidin coating
  • the length of a capture probe is typically in the range of from 10 nucleotides to about 200 nucleotides, such as from about 20 nucleotides to about 150 nucleotides, such as from about 30 nucleotides to about 100 nucleotides, and such as from about 40 nucleotides to about 80 nucleotides.
  • the target-specific binding region 102,102' of the target capture probe is typically from about 25 to about 150 nucleotides in length (e.g., 50 nucleotides, 100 nucleotides) and is chosen to specifically hybridize to a target sequence of interest.
  • the target-specific binding region comprises a sequence that is substantially complementary (i.e., at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or 100% identical) to a target sequence of interest.
  • the capture probe is about 70 nucleotides in length, comprising a target-specific region of about 35 nucleotides in length.
  • One of skill in the art can use art-recognized methods to determine the features of a target binding region that will hybridize to the target with minimal non-specific hybridization. For example, one of skill can determine experimentally the features such as length, based composition, and degree of complementarity that will enable a nucleic acid molecule (e.g., the target-specific binding region of a target capture probe) to specifically hybridize to another nucleic acid molecule (e.g., the nucleic acid target) under conditions of selected stringency, while minimizing non-specific hybridization to other substances or molecules.
  • a target gene sequence is retrieved from a public database such as GenBank, and the sequence is searched for stretches of from 25 to 150 bp with a complementary sequence having a GC content in the range of 45% to 55%.
  • the identified sequence may also be scanned to ensure the absence of potential secondary structure and may also be searched against a public database (e.g., a BLAST search) to ensure a lack of complementarity to other genes.
  • the capture oligonucleotides may be designed to bind to a target region at selected positions spaced across the target region at various intervals.
  • the capture oligo design and target selection process may also take into account genomic features of the target region such as genetic variation, G: C content, predicted oligo Tm, and the like.
  • the methods of the invention are used to capture and sequence a modified or mutated target, such as to determine the presence of a particular single nucleotide polymorphism (SNP) or deletion, addition, or other modification.
  • the set of target capture probes are typically designed such that there is a very dense array of capture probes that are closely spaced together such that a single target sequence, which may contain a mutation, will be bound by multiple capture probes that overlap the target sequence.
  • capture probes may be designed that cover every base of a target region, on one or both strands, (i.e., head to tail) or that are spaced at intervals of every 2, 3, 4, 5, 10, 15, 20, 40, 50, 90, 100 or more bases across a sequence region.
  • the selection of the target capture probes over a target region of interest is based on the size of the target region. For example, for a target region of less than 100 nucleotides in length, capture probes (either sense, antisense, or both) are typically designed to hybridize to target sequences spaced apart by from O to 100 nucleotides, such as every 45 nucleotides.
  • capture probes are typically designed to hybridize to target sequences spaced apart by from 0 to 200 nucleotides, such as at 45 to 65 nucleotide intervals.
  • a set of sense and antisense capture probes are designed that are each about 35 nucleotides in length and are spaced about 45 nucleotides apart across the target region (alternating sense/antisense) in order to saturate the region (e.g., "tile" across the region of interest).
  • a set of capture probes is designed to specifically bind to a plurality of target regions, such as the exons of a single gene or multiple genes, such as at least 5 genes, at least 10 genes, at least 20 genes, at least 50 genes, at least 75 genes, or more.
  • a set of capture probes is designed to specifically bind to target sequences across a genomic location, such as across a chromosomal region, and the capture probes are contacted with nucleic acid molecules from a total genomic library.
  • a set of capture probes is designed to specifically bind to target sequences across a genomic location, such as across a chromosomal region, and the capture probes are contacted with nucleic acids in a whole-transcriptome library in order to analyze the whole transcriptome across the chosen genomic locus, as described in Example 7.
  • a set of capture probes is designed to specifically bind to a genomic locus known to be associated with a clinical outcome or disease, or disease risk, for example, as described in Example 8.
  • the target capture probe 100, 100' comprises a capture reagent binding region 104 attached to a moiety 110 for binding to a capture reagent 400.
  • the solution-based capture method utilizes a binding interaction between a moiety 110 attached (directly or indirectly) to a capture probe 100, 100' and a capture reagent 400 to enable the selective separation of captured sequences (bound to the capture probe) from the bulk solution of captured and uncaptured DNA molecules.
  • the moiety 110 and capture reagent 400 may be any suitable binding partners such as, for example, biotin/streptavidin; epitope/antibody, or DNA hybridizing partners.
  • the moiety 110 is biotin and the capture reagent 400 is a streptavidin-coated bead 400, which is sorted with a magnetic sorting device 500.
  • the moiety 110 shown in FIGURE 4 is located at the 5' end of the capture probe, it will be understood by those of skill in the art that the moiety may alternatively be positioned at the 3' end of the target capture probe 100.
  • the moiety 110 and capture reagent 400 may be an epitope/antibody pair, such as a digoxin moiety that is bound by digoxin antibodies or a fluorescein moiety that is bound by fluorescing antibodies, or other small epitope/antibody configurations.
  • the moiety 110 and capture reagent 400 may be DNA hybridization partners.
  • the moiety 110 on the capture probe may be a sequence that is complementary to an oligonucleotide affixed to beads 400.
  • the capture probes 200 comprise a target-sequence specific binding region 202, 202' and a capture reagent binding region 204 that hybridizes to a universal adaptor oligonucleotide 300 comprising a moiety 310 that binds to a capture reagent 400.
  • step B the target-specific binding region 202 of sense 200 or antisense 200' target capture probes bind to a substantially complementary nucleic acid sequence contained in an insert region 10 or 10' of a nucleic acid molecule 50 in the library.
  • the universal adaptor oligonucleotide 300 is present at an equal concentration as the capture probes 200, and hybridize to the capture reagent binding region 204.
  • the moiety 310 e.g., biotin
  • attached to the universal oligo adaptor 300 is then contacted with a capture reagent 400 (e.g., a magnetic bead) having a binding region 410 (e.g., streptavidin coating) and the complex is pulled out of solution with a sorting device 500 (e.g., a magnet) that binds to the capture reagent 400.
  • a capture reagent 400 e.g., a magnetic bead
  • a binding region 410 e.g., streptavidin coating
  • the methods of solution-based capture 650 include the step 652 of providing a library of nucleic acid molecules comprising nucleic acid target insert sequences of interest flanked by a first primer binding region on one end and a second primer binding region on the other end (e.g., produced as shown in step 630, from FIGURE 3).
  • the library of nucleic acid molecules 5OA, 50B is annealed with a set of capture probes, each capture probe comprising a region that hybridizes to a target sequence contained in a library insert.
  • the capture probes 100 comprise a moiety 110 (e.g., biotinylated) for binding to a capture reagent 400 (e.g., streptavidin-coated beads).
  • the library of nucleic acid molecules 5OA, 50B is annealed with a combination of a set of capture probes 200, each comprising a region 204 that hybridizes to a universal adaptor oligo 300 and an equimolar amount of universal adaptor oligos 300 comprising a moiety 310 for binding to a capture reagent 400.
  • the nucleic acid molecules in the mixture are then denatured (i.e., by heating to 94 degrees) and allowed to cool to room temperature.
  • the annealing step is carried out in a high salt solution comprising from 100 mM to 2 M NaCl with the addition of 0.1% triton XlOO (or tween or NP40) nonionic detergent.
  • an amount of capture reagent is added to the annealed mixture sufficient to generate a plurality of complexes, each containing a nucleic acid molecule, a capture probe (or a capture probe and a universal adaptor oligo), and a capture reagent.
  • the mixture is incubated at room temperature with mixing for about 15 minutes.
  • the complexes formed in step 655 are isolated or separated from solution with a sorting device 500 (e.g., a magnet) that pulls or sorts the capture reagent 400 out of solution.
  • a sorting device 500 e.g., a magnet
  • the sorted complexes bound to the capture reagent 400 are washed with a low salt wash buffer (less than 1O mM NaCl, and more preferably no NaCl) to remove non-target nucleic acids.
  • a low salt wash buffer is 10 mM Tris pH
  • the low salt wash optionally contains from 15% to 30% formamide, such as 25% formamide
  • the capture reagent 400 bound to the complexes i.e., magnetic beads
  • the capture reagent 400 bound to the complexes are resuspended in the low salt wash buffer and rocked for 5 minutes, then sorted again with the sorting device (magnet).
  • the wash step may be repeated 2 to 4 times.
  • the nucleic acid molecules containing the target sequences are eluted from the complexes bound to the capture reagent as follows.
  • the washed complexes bound to the capture reagent 400 are resuspended in water, or in a low salt buffer (i.e., osmolarity less than 100 millimolar), heated to 94°C for 30 seconds, the capture reagent (i.e., magnetic beads) are pulled out using a sorting device (i.e., magnet), and the supernatant (eluate) containing the target nucleic acid molecules is collected.
  • a sorting device i.e., magnet
  • the eluate is amplified in a PCR reaction with a first PCR primer that binds to the first primer binding site in the first linker and a second PCR primer that binds to the second primer binding site in the second linker, producing a once-enriched library that can be optionally sequenced at step 680.
  • the once-enriched library may be further processed according to steps 654-670 using the same set of capture probes in each round of enrichment to generate a library that is twice-enriched or three-times enriched, etc., for the target sequences of interest prior to sequence analysis.
  • the ratio of the concentration of the DNA target in the first and second round of enrichment to the concentration of capture oligo is a concentration of about 500 ng/ml DNA target to a concentration in the range of from about 1 nM to 10 nM of capture oligo. In one embodiment, the ratio of the concentration of DNA target in the third round of enrichment to concentration of capture oligo is a concentration of about 500 ng/ml of the twice-enriched library to a concentration of about 1 nM of capture oligo. In one embodiment, the first round of enrichment (steps 654-670 shown in
  • FIGURE 6 is carried out with a first set of capture probes designed to target a first set of targets, followed by a second round of enrichment that is carried out with a second set of capture probes designed to target a second set of targets.
  • the capture reagent (400) comprises streptavidin coated magnetic beads, each bead having a binding capacity of approximately 50 pmol of biotinylated double-stranded DNA/50 ⁇ l of beads.
  • about 50 ⁇ l of the streptavidin coated magnetic beads are added to about 5 ⁇ g of the annealed nucleic acids (e.g., in the first and second rounds of enrichment).
  • about 5 ⁇ l of the streptavidin coated magnetic beads are added to about 5 ⁇ g of the annealed nucleic acids (e.g., in the third round of enrichment).
  • the solution-based capture methods according to the various embodiments described herein may be used to produce a level of target fragment specific enrichment in the range of 500- to 900-fold in the first round of enrichment, with a 50-fold higher level of enrichment in the second round (i.e., 25,000- to 45,000-fold total enrichment levels).
  • the final round of enrichment may be carried out with a limiting amount of capture probe to library, in order to allow for the normalizing or leveling of target gene sequences in the enriched library, such that there will be a broad distribution in the frequency of amplified targets.
  • DNA synthesis of the various oligonucleotides of the invention can be carried out by any art-recognized chemistry, including phosphodiester, phosphotriester, phosphate triester, or N-phosphonate and phosphoramidite chemistries (see e.g., Froehler et al., Nucleic Acid Res. 74:5399-5407, 1986; McBride et al., Tetrahedron Lett. 24:246-248, 1983).
  • oligonucleotide synthesis are well known in the art and generally involve coupling an activated phosphorous derivative on the 3' hydroxyl group of a nucleotide with the 5' hydroxyl group of the nucleic acid molecule (see, e.g., Gait, "Oligonucleotide Synthesis: A Practical Approach,” IRL Press, 1984).
  • capture probes 100, 100' are synthesized to include RNA residues (i.e., DNA/RNA hybrid molecules) and/or unnatural bases such as inosine that have altered base pairing and/or have modified backbone sequences such as thiophosphate.
  • RNA residues i.e., DNA/RNA hybrid molecules
  • unnatural bases such as inosine that have altered base pairing and/or have modified backbone sequences such as thiophosphate.
  • This example describes the use of a PCR-based approach to generate a sequencing-ready library of the exon amplicons of 5 genes of interest, with an optional further modification to include the use of molecular bar code sequences.
  • Illumina sequencing platform is the targeted resequencing of particular regions of a sequenced genome, such as the human genome.
  • the targeted regions were the coding exons of 5 human genes-AKTl, KRAS, PIK3CA, PTEN, and TP53.
  • PCR was used to retrieve 52 exonic regions derived from these 5 genes and methods are described herein for converting these DNA amplicons into fragmented samples flanked by linkers containing primer binding sites suitable for sequencing.
  • the output of sequences from a system such as the Illumina platform is of sufficient quantity that it is conceivable to sequence several samples at once. To analyze samples simultaneously, each sample must be uniquely tagged.
  • One method for tagging validated in this example, is to append a specific sequence of nucleotides, with each attached sequence unique to each sample, between the sequencing initiation site and the fragmented library segments that are to be sequenced. In this way, the first few bases of sequence uniquely identify the sample while the remaining sequence will be derived from the target regions that are being analyzed in that sample.
  • molecular bar code tags of 3 nucleotides were attached to unique sequencing libraries, and all 64 possible combinations of these codes were combined into a single sequencing library. Analysis of the output sequences confirmed that each code was uniquely associated with the appropriate library sequences. By extension, varying the code length to n bases makes it possible to generate 4 ⁇ codes.
  • This example demonstrates that the all of the regions included in pooled PCR fragments that were sequenced were successfully converted into fragments flanked by linkers that generated sequence information. Moreover, this example also shows that molecular bar codes can be used to multiplex samples into a single sequencing reaction from which sequence information unique to each sample can be subsequently extracted by computational analysis.
  • TP53 were selected using an exon primer selection software entitled "Exon Primer,” available on the UCSC Genome Bioinformatics browser at http://genome.ucsc.edu/. Five pairs of PCR primers per exon were initially selected for evaluation for PCR amplification of each exon in the 5 gene set. PCR primers were chosen using the following criteria:
  • the primers were chosen to amplify across more than 1 exon.
  • a target primer annealing temperature of 6O 0 C with a GC clamp, which is comprised of one or more G: C base pairs at the 3' primer terminus and is intended to stabilize the termini of the primer template duplex.
  • a maximum length of a mononucleotide repeat (e.g., AAAA) of 4 nt.
  • Primer sequences were also masked against common repeat elements found in the human genome such that primer pairs with a potential to amplify multiple segments of the genome were removed.
  • PCR primer was selected and tested as described below. Primers were delivered in 10 individual 96 well plates as 100 ⁇ l of a 100 ⁇ M stock. Stock primers were diluted 1 :50 in water to create working primers that were 2 ⁇ M. Stock primers and working primers were stored at -2O 0 C.
  • PCR reactions were carried out using the candidate set of primers as described below and the reactions were evaluated on agarose gel to determine if the correct sized PCR product was generated.
  • the 51 exon amplicons were PCR amplified from genomic DNA using the primer pairs and conditions shown in TABLE 3. These PCR products were then pooled and purified over QiaQuick ® columns (Qiagen), which removes DNA fragments less than approximately 40 bp. The purified pooled PCR products were present at 50 ng/ ⁇ l in a size range of approximately 50 bp to 900 bp.
  • bovine pancreatic deoxyribonuclease I (DNase I) induces random double-stranded breaks in DNA in the absence of Mg ++ and in the presence ofMn ++ (Anderson, S., Nucleic Acids Res. 9(13):3015-3027 (1981); Melgar, E., et al., J. Biol. Chem. 243(17)-A4O9-16 (1968)). Therefore, bovine pancreatic DNase I (New England Biolabs Catalog #M0303S) was used to randomly fragment the pool of exon amplicons to generate a sequencing library as described below.
  • DNase I bovine pancreatic deoxyribonuclease I
  • Bovine pancreatic DNase I treatment was tested over a range of concentrations of 0.004U, 0.002U, and 0.00 IU per ⁇ l (in the absence of Mg++ and in the presence of
  • the Dnase I reaction was incubated at room temperature for 10 minutes, stopped with 0.2 volume of 100 mM EDTA, and run on an agarose gel to determine the size range resulting from the Dnase I digestion.
  • the Dnase I reaction was then scaled up to digest 10 ⁇ g total pooled PCR fragments under the conditions described above.
  • the Dnase I digested material was run over a Qiaquick ® column (removing fragments smaller than about 50 bp).
  • the purified DNA was then concentrated with Ethanol precipitation, by combing the 200 ⁇ l purified DNA, 20 ⁇ l of 3M Sodium Acetate, 3 ⁇ l of Glyco-blue, and 500 ⁇ l 100% ETOH. A total of 4.5 ⁇ g DNA was recovered (45 ng/ ⁇ l in 100 ⁇ l total volume).
  • the Quick Blunting ® Kit includes a reaction mixture with T4 polymerase (which has both 3' to 5' exonuclease activity and 5' to 3' polymerase activity) and T4 polynucleotide kinase (for phosphorylation of the blunt-ended DNA for subsequent ligation to the stem-loop adaptors), resulting in a final fragment concentration of 40 ng/ ⁇ l.
  • oligonucleotide linkers containing PCR primer binding sites were ligated to blunt-ended library fragments.
  • the oligo linkers were designed as single DNA oligonucleotides capable of self-annealing to form a stem-loop secondary structure.
  • the stem forms a blunt ended dsDNA segment suitable for ligation to the blunt-end library fragments.
  • stem sequences were utilized that were 15 to 18 nucleotides in length with roughly equal representation ofG:C and A:T base pairs. Such stem sequences are predicted to form stable dsDNA structures below their predicted melting temperatures of ⁇ 45°C.
  • the formation of the ligatable dsDNA stem is a self: self intermolecular reaction that is highly efficient and each adaptor has only one dsDNA termini capable of ligation.
  • self-annealing stem structures that range in size from 5 nucleotides to > 100 nucleotides may be included in the stem loop adaptor.
  • a pair of stem-loop linker oligonucleotides shown as a first stem-loop linker 20 and a second stem-loop linker 30, was designed for ligation to the ends of each DNase I digested and blunt end-polished double-stranded DNA fragment 10.
  • This ligation reaction generated a mixture of ligation products including the target molecules 5OA and 50B comprising a plurality of DNA inserts 10 flanked by the first stem-loop linker 20 at one end and the second stem-loop linker 30 at the other end, as well as unwanted byproduct ligation products 60, 70 comprising a plurality of DNA inserts 10 flanked at both ends by either the first stem-loop linker 20 or flanked at both ends by the second stem-loop linker 30, as shown in FIGURE 1 at step D.
  • the first stem-loop linker oligonucleotide 20 comprises a 5' region 24 with a sequence that is complementary to a sequence located in the 3' region 28 and an intervening region 26 between the 5' and 3' region that forms a loop structure. Also located in the first stem-loop linker oligonucleotide 20 is a sequence 22 that is complementary to a first primer binding region 82 that may be positioned in the intervening region 26 or in the stem region.
  • the second stem-loop linker oligonucleotide 30 comprises a 5' region 34 having a sequence that is complementary to a sequence located in the 3' region 38 and an intervening region 36 between the 5' and 3' region that forms a loop structure. Also located in the second stem-loop linker oligonucleotide 30 is a sequence 32 that is complementary to a second primer binding region 92 that may be positioned in the intervening region 36 or in the stem region.
  • the 5' region 34 and 3' region 38 hybridize together, resulting in the stem-loop linker oligonucleotide 30 structure with a double-stranded stem 34 and 38 with an intervening region 36 that forms a loop structure.
  • the sequences 22, 32 are complementary to the first and second primer binding regions 82, 92, which contain primer binding sites for binding to forward and reverse PCR primers, as described in more detail below.
  • each stem-loop linker 20, 30 is typically at least 40 nucleotides, such as at least 45 nucleotides, at least 50 nucleotides, at least 55 nucleotides, at least 60 nucleotides, at least 65 nucleotides, at least 70 nucleotides, up to a maximum length of about 200 nucleotides.
  • the stem-loop linkers are from about 45 nucleotides in length to about 70 nucleotides in length.
  • 5' and 3' stem-loop linkers are key elements of the library construction since they provide universal primer binding sites for subsequent PCR and may contain primer binding sites/anchors for sequencing cluster generation and they can be used to introduce bar-codes for sample multiplexing.
  • suppression PCR may be used to prepare a sequencing-ready library enriched for the target molecules 50A and 5OB comprising heterogeneous stem-loop adaptors at each end of the insert, as shown in the PCR products in FIGURE 1 at step D.
  • step A at least one of the stem-loop linkers
  • the bar code sequence 40 may be positioned at the 3' end of the linker 20, so that it is adjacent the insert 10 after ligation. As shown in FIGURE 1, a complementary sequence 40' is present on the 5' end of the linker 20.
  • SEQ ID NO: 105 has a total length of 67 nucleotides, and consists of a 5' 15 nucleotide stem hybridizing region 24 (underlined), a 37 nucleotide intervening loop region 26 and a 3' 15 nucleotide stem hybridizing region 28 (underlined), with a sequence 22 complementary to the first PCR primer binding region 82 shown in italics.
  • SEQ ID NO: 106 has a total length of 49 nucleotides, and consists of a
  • SEQ ID NO: 107 is a total length of 49 nucleotides, and consists of a 15 nucleotide stem hybridizing region 34 (underlined), a 19 nucleotide intervening loop region 36, and a 3' 15 nucleotide stem hybridizing region 38 (underlined), with a sequence 32 complementary to the second PCR primer binding region 92 shown in italics.
  • first 20 and second 30 stem-loop linker oligonucleotides were ligated to the blunt end-polished fragments 10 as follows.
  • a test experiment was carried out to determine the conditions for ligation of stem- loop linkers to a double-stranded DNA fragment with phosphorylated blunt ends.
  • test vector pCR2.1 (Invitrogen, Carlsbad California) was digested with PvuII to generate blunt ends.
  • Stem-loop linkers (SEQ ID NO: 105 and SEQ ID NO: 107) and
  • a series of ligation reactions were set up to determine the ability to ligate stem-loop linkers with blunt end-polished DNase I fragmented exon amplicon pools to generate a sequencing library.
  • ligation mixture was incubated for 10 minutes at room temperature, diluted with 180 ⁇ l of TEzero (lO mM Tris pH 7.6 and 0.1 mM EDTA), and was used as a template in the suppression PCR reaction described below.
  • TEzero lO mM Tris pH 7.6 and 0.1 mM EDTA
  • the first stem-loop linker 20 adds information to the 5' end of the double-stranded insert 10; however, this information is on the wrong strand to be useful in PCR amplification, therefore this information needs to be copied over to the 3' end to create a primer binding site.
  • step D PCR products
  • the stem-loop linkers attach randomly to library fragments, resulting in an initial population of ligation products where half the ligation products have the same linker termini on each end (homogeneous linker ends) and half the ligation products possess different linker termini (heterogeneous linker ends).
  • the phenomenon of suppression PCR (P.D. Siebert et al., Nucleic Acids Res.
  • suppression PCR refers to the phenomenon that DNA segments that contain perfect inverted repeats at their termini longer than 40 nucleotides are poor substrates for amplification by PCR.
  • the conceptual model is that these molecules form spontaneous intramolecular stem-loop structures that occlude PCR primer binding and subsequent amplification.
  • the empirical observation is that molecules with perfect inverted repeat termini >40 nt amplify poorly relative to similar DNA fragments with heterogeneous ends.
  • stem loop adaptors add either 50, 67, or 73 nucleotides of additional sequence to the ends of ligated DNA fragments.
  • molecules with homogenous ends are long enough to evoke suppression PCR effects; hence, molecules with heterogeneous ends (e.g., 5OA, 50B) are preferentially amplified and therefore the library is enriched for the sequencing-ready target molecules 5OA, 5OB, by the PCR reaction that follows ligation of the stem-loop linkers, resulting in a library enriched for sequencing-ready target molecules.
  • heterogeneous ends e.g., 5OA, 50B
  • first stem-loop linkers 20 e.g., SEQ ID NO:105
  • second stem-loop linkers 30 e.g., SEQ ID NO:106
  • suppression PCR was used as described below in order to selectively amplify the target 5OA, 50B ligation products to generate a library of nucleic acid molecules that are suitable for direct use as sequencing templates (i.e., sequence ready).
  • the unwanted 50% ligation byproducts 60, 70 are refractive to PCR amplification because the first stem-loop linker oligonucleotide (e.g., SEQ ID NO:105) and second stem-loop linker oligonucleotide (e.g., SEQ ID NO:106) are long (i.e., greater than 40 nucleotides) and result in a stem-loop structure with the fragment insert 10 as the intervening region with the stem formed by hybridizing linker regions.
  • first stem-loop linker oligonucleotide e.g., SEQ ID NO:105
  • second stem-loop linker oligonucleotide e.g., SEQ ID NO:106
  • a post-ligation PCR amplification step is used to selectively enrich the ligation products having the desired target structure 50A, 50B with heterogeneous linker termini (shown as PCR products in FIGURE 1, step D), as follows.
  • a first PCR primer 52 that hybridizes to the first PCR primer binding site 82 and a second PCR primer 54 that hybridizes to the second PCR primer binding site 92 generated in the second strand during the PCR fill-in reaction of linkers 20 and 30, respectively, are used to selectively amplify the ligation products with the target structure 5OA, 50B.
  • First PCR primer 52 5'-AATGATACGGCGACCACCGA-S' (SEQ ID NO:109)
  • Second PCR primer 54 5'-CAAGCAGAAGACGGCATACG-S' (SEQ ID NO: 110) PCR Reaction Mixture (with 5% DMSO);
  • Taq Polymerase (native Taq 5U/ ⁇ l, Invitrogen) 1 ⁇ l EXPANDPLUS® Polymerase (5U/ ⁇ l, Roche) 100 ⁇ l total
  • Amplicons from the 5 genes-AKTl, KRAS, PIK3CA, PTEN, and TP53 ⁇ were generated as described above and pooled in eight unique configurations. As shown below in TABLE 4, each pool in the set of 8 pools has a unique composition of exonic amplicons. Each of these eight unique pools was fragmented, blunt-ended, and then each pool was itself attached to a set of eight bar-coded stem-loop linkers that were synthesized, using the stem-loop first linker (SEQ ID NO: 105), with an additional 3 nucleotide sequence tag (molecular bar code) added to the 3' end of the stem-loop linker. In this way, each of 8 unique pools was attached to a set of eight bar codes, generating the complete set of 64 bar coded samples shown in TABLE 5.
  • one representative bar-coded forward stem-loop linker oligonucleotide designated as the first bar code in Pool #1 ("AAA") in TABLE 5 (shown in italics) is added to SEQ ID NO: 105, resulting in the following sequence: 5'77TAGATCGGAAGAGCGTAATGATACGGCGACCACCGACACTCTrTC CCTACACGACGCTCTTCCGATCT ⁇ A43' (SEQ ID NO:108).
  • the 8 pools were made by generating amplicons for the 5 selected genes, as described in Example 1, which were used to make eight unique pools by (1) leaving out one of eight rows of PCR fragments and pooling 20 ⁇ l of the remaining samples, (2) adding an additional 100 ⁇ l of weakly amplified products (unless they were designated to be left out), and (3) adding 200 ⁇ l of a unique PCR fragment to each pool.
  • the pools were purified over four Qiaquick® columns. The samples were eluted in 60 ⁇ l of elution buffer per column, yielding about 200 ⁇ l. DNA quantitation by nanodrop revealed a DNA concentration range of 120 to 150 ng/ ⁇ l, with a total yield of 24-30 ⁇ g.
  • amplicons Eight pools comprising various combinations of amplicons were mixed as shown in TABLE 4.
  • the amplicon pools were treated with DNase I in the presence of Mn ++ as described in Example 1 to yield DNase I digested fragments, which were then purified over Qiaquick ® columns (Qiagen Corp.) to generate a pool of fragments in the size range averaging in length from about 50 bp to about 500 bp.
  • the purified fragments were then filled in as described in Example 1 with the Quick Blunting ® Kit (New England Biolabs, Catalog #E 120 IL) according to the manufacturer's instructions.
  • the Quick Blunting® Kit includes a reaction mixture with T4 polymerase (which has both 3' to 5' exonuclease activity and 5' to 3' polymerase activity) and T4 polynucleotide kinase (for phosphorylation of the blunt-ended DNA for subsequent ligation to the stem-loop linkers).
  • T4 polymerase which has both 3' to 5' exonuclease activity and 5' to 3' polymerase activity
  • T4 polynucleotide kinase for phosphorylation of the blunt-ended DNA for subsequent ligation to the stem-loop linkers.
  • a master mix was first prepared: 20 ⁇ l of blunt end (filled-in), fragmented amplicon pool DNA
  • pool 1 SEQ ID NO: 105+ first to eighth bar code sequence shown in TABLE 5
  • One ⁇ l of ligase was then added to each tube and incubated for 10 minutes.
  • the 20 ⁇ l ligation mix was then diluted 10-fold into TEzero and 2 ⁇ l of this was added to subsequent 20 ⁇ l PCR reactions as follows.
  • First PCR primer 5'-AATGATACGGCGACCACCGA-S' (SEQ ID NO: 109) 2 ⁇ l (4 ⁇ M) Second PCR primer: 5'-CAAGCAGAAGACGGCATACG-S' (SEQ ID NO: 109)
  • each row corresponds to the sequencing read density (i.e., number of sequencing reads) associated with a particular 3 nucleotide barcode sequence and each column corresponds to the sequencing reads associated with each gene exon region to which the sequence read aligned.
  • FIGURE 2A boxes are white (not shaded) if abundant sequencing reads were detected (>80% of the average read counts over all bar codes) and black (shaded) if few reads were detected ( ⁇ 10% of the average counts over all bar codes).
  • FIGURE 2 A shows both the expected and observed distribution of reads, which exhibited an identical distribution and could therefore be represented in a single figure. Notably, the pattern of abundant and underrepresented reads was perfectly consistent for all of the bar codes associated with pool 1 and pool 2, and, although not shown, for all eight groups of bar codes analyzed. These results demonstrate that all eight barcode sequences ligated to pool 1 or pool 2 DNA exhibited that same pattern of read densities (which was also true of the entire set of 64 codes used in this experiment—data not shown).
  • FIGURE 2A The results shown in FIGURE 2A are summarized in FIGURE 2B, in which the expected and observed pattern of read alignment densities for each pool of bar coded samples is shown.
  • FIGURE 2B To obtain the sequencing read densities for the pools, the data from the eight bar codes that formed each pool were summed and analyzed relative to the average density of sequencing reads.
  • the results can be shown as a single FIGURE because the expected and observed results were identical (i.e., the results shown in FIGURE 2A matched the composition of the pools prepared as described in TABLE 4).
  • pool 1 is a pool of the amplicons listed in TABLE 4 that were generated using first adaptor stem loop primer pool 1 codes: (AAA; AGA, CAA, CGA, GAA, GGA, TAA, and TGA). It will be understood by those of skill in the art that alternative arrangements of the length of the nucleotide tag can provide varying levels of complexity.
  • a 1 nucleotide tag provides a 4 plex
  • a 2 nucleotide tag provides a 16 plex
  • a 3 nucleotide tag provides a 64 plex
  • a 4 nucleotide tag provides a 256 plex
  • sequence information from, for example, the Illumina GA2 ® sequencer far exceeds the data requirements for analysis of individual samples.
  • Multiplexing strategies are required to make full use of these emerging sequencing technologies and to increase the throughput of samples that can be analyzed.
  • the results described in this example validate the feasibility of adding trinucleotide molecular barcodes to individual samples, facilitating the simultaneous analysis of 64 samples.
  • Other configurations of bar code complexity (nucleotide length) can be applied to samples that require greater or lesser sequence coverage.
  • this example demonstrates a method of generating a sequencing-ready library 600 comprising the steps of fragmenting a starting population of DNA molecules 610, attaching stem-loop linkers with primer binding sides and optional bar codes 620, and suppressing PCR 630 to generate the sequencing-ready library, which can be sequenced 640.
  • the starting population of DNA molecules is PCR amplified target regions; therefore, the sequence ready library is already enriched for the sequencing target(s) of interest.
  • the method further comprises the steps of solution-based capture 650 to enrich the library (e.g., a library generated from total genomic DNA or whole amplified transcriptome) for the sequencing targets of interest prior to sequencing, as described in Examples 3-8 and shown in FIGURE 6.
  • the library e.g., a library generated from total genomic DNA or whole amplified transcriptome
  • This example describes the generation of a sequencing-ready library of genomic DNA inserts.
  • libraries can be used for solution-based capture targeted resequencing methods as described below, for analysis of sequence-based chromosomal copy number variation or for biomarker screening/discovery.
  • a collection of oligonucleotides complementary to target resequencing regions is annealed to a whole genome fragment library.
  • the collection of sequences bound to these probes can then be characterized by sequencing.
  • the overall procedure, termed "solution-based capture,” is an alternative to PCR that can be scaled to very large resequencing regions. This example describes the construction and characterization of genomic DNA libraries to be used in such a procedure.
  • this example describes an embodiment of the method of generating a sequencing-ready library 600 by fragmenting a starting population of genomic DNA 610, ligating stem-loop linkers to the DNA fragments 620, suppressing PCR to enrich the library for ligation products with heterogeneous linkers 630, and followed by one or more rounds of solution-based capture 650 to enrich the library for sequencing targets of interest.
  • genomic DNA was used as the starting material for the library, although cDNA could also be used as starting material to generate a library.
  • the process of generating the library using stem-loop linkers was nearly identical to that described in
  • Library construction involved the generation of inserts by fragmentation of genomic DNA or cDNA, followed by blunt-end polishing and ligation of 5' and
  • the 5' and 3' stem-loop linkers are key elements of the library construction because they provide universal anchors for subsequent PCR and optional sequencing cluster generation, they can be used to introduce bar-codes for sample multiplexing, as described in Example 1, and suppressing PCR may be used to enrich for a library containing heterogeneous stem-loop adaptors at each end of the insert, as shown in FIGURE 1 step C, which can be used as templates for sequencing.
  • stem-loop linkers The sequence design of the stem-loop linkers is described in Example 1.
  • An exemplary set of stem-loop linkers used in this example are SEQ ID NO: 105 (first stem- loop linker #1) and SEQ ID NO: 107 (second stem-loop linker #2).
  • the forward stem-loop linkers (SEQ ID NO: 105) were bar coded as follows: Four bar codes were used in this experiment, which were chosen to represent all four bases in each of the three base positions, and homopolymers were avoided. In order to reduce the level of primer-dimer background material, prior to ligation, the stem-loop linkers were pre-treated with Antarctic alkaline phosphatase (New England Biolabs Catalog #M0289S), as described in Example 1. 100 ⁇ M stem-loop linkers (SEQ ID NO:105 and SEQ ID NO:107) were dephosphorylated and reconcentrated to approximately 10 ⁇ M as follows:
  • reaction was incubated at 37 0 C for one hour and heat inactivated at 65 0 C for 5 minutes.
  • the reaction mixture was then split into two tubes and precipitated by adding
  • genomic DNA was fragmented by sonication prior to DNAse I treatment as follows.
  • Genomic DNA was diluted in water or in a Tris buffer (2 ⁇ g DNA with 500 ⁇ L 50 mM Tris) without EDTA and without Mn ++ (Note: EDTA will chelate the Mn ++ ions needed by the DNAse I in the next step). If EDTA was present in the sonication buffer, then a clean-up step (e.g., Qiagen Qiaquick ® column) was used to remove the EDTA prior to DNAse I treatment.
  • a clean-up step e.g., Qiagen Qiaquick ® column
  • the sonicated sample was then treated with DNAse I as described below.
  • DNase I bovine pancreatic deoxyribonuclease I
  • the DNase I reaction was incubated at room temperature for 10 minutes and stopped by the addition of 0.2 volumes of 100 mM EDTA and immediately transferred to ice.
  • the dilution of DNAse was chosen to generate fragments averaging in length from about 50 to about 500 bp, which was determined using a DNase I dilution series as described in Example 1.
  • the reaction mixture was then purified over a Qiaquick ® spin column (Qiagen), with a recovery of about 40% of the input DNA in about 200 ⁇ l, with a size cut-off below about 40 bp.
  • the column purified DNA was then concentrated by precipitation and resuspended in water to a final concentration of 80 ng/ ⁇ l.
  • the ligation reaction was incubated at room temperature for 10 minutes (not heat inactivated) then diluted with 180 ⁇ l of TEzero (10 mM Tris pH 7.6 and 0.1 mM EDTA) and stored at -20 0 C or used in the PCR amplification step described below.
  • TEzero 10 mM Tris pH 7.6 and 0.1 mM EDTA
  • the overall concentration of vector plus insert was preferably between 1 to 10 ⁇ g/ml for efficient ligation.
  • vecto ⁇ insert ratios between 2:1 and 6:1 were preferable. It was observed that vecto ⁇ insert ratios below 2:1 resulted in lower ligation efficiency, while vector: insert ratios above 6:1 promoted multiple inserts.
  • PCR was used to produce >5 ⁇ g of product for the first round of solution-based target capture and enrichment. In order to generate this amount of product, 4X 100 ⁇ l PCR reactions were carried out for each library generated.
  • First PCR primer 5'-AATGATACGGCGACCACCGA-3 1 (SEQ ID NO: 109)
  • Second PCR primer 5'-CAAGCAGAAGACGGCATACG-S' (SEQ ID NO: 110)
  • the minimum size range of the library was expected to be >130 bp, which is the sum of the adaptor sequences left over after PCR (90 bp) and the minimum insert size of 40 bp. Smaller bands are indicative of ligated adaptor dimers and libraries with detectable quantities of this material were rejected.
  • a 100 ⁇ l PCR reaction mixture was purified over a 100 ⁇ l
  • the purified DNA comprises a sequence-ready library (at step 630), which can be directly sequenced (at step 640) or enriched for target sequences (as shown in FIGURE 3, steps 650-670) prior to sequence analysis.
  • qPCR quantitative PCR
  • the % raw abundance of library samples relative to the reference genomic DNA was then calculated. It was observed that the abundances of gene content in the libraries fell short of the reference for gene content. While not wishing to be bound by theory, the reason for this was believed to be two-fold ⁇ first, enzymatic shearing created a high likelihood of digesting within a qPCR TaqMan primer binding site, therefore sheared DNA would be expected to have a lower gene-specific activity than an unsheared reference genomic DNA control; second, the stem-loop linkers represented a substantial mass in the library (e.g., in a library with 100 bp inserts, half the mass of the library is adaptor). Therefore, a substantial portion of the mass of library DNA is comprised of ligated linkers.
  • TABLE 6 shows the relationship between insert size, the % of library composed of adaptor, and the TaqMan signal detected.
  • the key point for assessing library quality was that gene content was readily detectable (target genomic DNA is present in the initial library and the insert size is >50 bp) and that insert size is not excessive, as judged by gel appearance combined with qPCR.
  • the agarose gels (not shown) produced the desired size distribution of fragments, ranging in size from >130 bp to ⁇ 800 bp; the majority of fragments were in the 200-400 bp size range.
  • the qPCR signal for genes is reported as a percent of the signal detected in unsheared genomic DNA.
  • the combined values for four genes and the numerical averages for each library are shown in columns.
  • the 100+- control and 200+ controls corresponded to well-characterized genomic libraries with known insert sizes and gene content.
  • the nine libraries reported as an example all produced qPCR measurements consistent with the creation of useful libraries.
  • Gel analysis showed a desirable distribution of fragment sizes and qPCR gave consistent results showing gene content metrics comparable to the two well-characterized control samples.
  • the generation of a genomic library followed by solution-based sequence capture eliminates the need for the initial step of individually PCR-amplifying the regions of interest. Therefore, as shown in FIGURE 3, the use of solution-based capture requires manipulation of a single sample throughout the resequencing library construction process, regardless of the size or complexity of the target region that is being addressed.
  • An additional advantage is that the capture of target sequences can be applied in several rounds, with PCR amplification of the enriched library fractions between steps. This allows for the creation of resequencing samples that are largely composed of target sequences.
  • the central basis of solution-based direct capture is the annealing of the library comprising ligation products 5OA, 5OB with sense 100 and anti-sense 100' capture probes, thereby forming a plurality of bi-molecular DNA complexes (at step B) between a target strand (e.g., 50A) and a target insert sequence-specific capture probe 100 comprising a moiety 110 that binds a capture reagent 400.
  • these bi-molecular DNA complexes are bound by the capture reagent 400, such as streptavidin-coated 410 paramagnetic beads, which are then purified away from the bulk solution by magnetic retention to a magnetic source 500.
  • a representative nucleic acid molecule 5OA is shown that is a member of a library comprising a population of double-stranded nucleic acid molecules 5OA, 5OB.
  • Each double-stranded nucleic acid molecule 5OA, 5OB in the library comprises an insert 10 with a candidate nucleic acid sequence flanked by a first linker region 20 and a second linker region 30.
  • this example was carried out using a library made from fragmented genomic DNA, it will be understood by those of skill in the art that the population of inserts 10 with candidate nucleic acid sequences for solution-based capture may be generated from genomic DNA or cDNA (as described in Example 2) or from PCR products (as described in Example 1).
  • a population of sense target capture probes 100 and a population of anti-sense target capture probes 100' are mixed with the denatured library comprising sense 50A, 5OB nucleic acid molecules and anti-sense 50A', 50B' nucleic acid molecules.
  • Each sense target capture probe 100 comprises a target-specific binding region 102 having a nucleic acid sequence that is substantially complementary to the sense strand of a target insert 10 of interest, and a region 104 for attaching a moiety 110 for binding to a capture reagent 400 (e.g., streptavidin-coated magnetic beads).
  • each anti-sense target capture probe 100' comprises a target-specific binding region 102' having a nucleic acid sequence that is substantially complementary to the anti-sense-strand of a target insert 10' of interest, and a region 104 for attaching a moiety 1 10 for binding to a capture reagent 400 (e.g., streptavidin-coated magnetic beads).
  • a capture reagent 400 e.g., streptavidin-coated magnetic beads.
  • the target-specific binding region 102 of sense 100 or antisense 100' target capture probes bind to a substantially complementary nucleic acid sequence contained in an insert region 10 or 10' of a nucleic acid molecule 50 in the library.
  • the moiety 110 (e.g., biotin) attached to the capture probe 100, 100' is then contacted with a capture reagent 400 (e.g., a magnetic bead) having a binding region 410 (e.g., streptavidin coating) and pulled out of solution with a sorting device 500 that binds to the capture reagent 400, such as a magnet.
  • a capture reagent 400 e.g., a magnetic bead
  • a binding region 410 e.g., streptavidin coating
  • the solution-based capture method may be used to enrich a library for target sequences of interest.
  • a sequencing-ready library generated from total genomic DNA 630 generated using the methods described, supra, includes a population of double-stranded nucleic acid molecules 50, each double-stranded nucleic acid molecule 50 comprising an insert 10 having a candidate nucleic acid sequence flanked by a first linker region 20 and a second linker region 30.
  • Within the population of double-stranded nucleic acid molecules 50 in the library there exists a subpopulation of molecules 50 that contain inserts 10 with target nucleic acid sequences within a greater population of molecules 50 that contain inserts 10 with non-target nucleic acid sequences.
  • the subpopulation of molecules 50 that contain inserts 10 with target nucleic acid sequences may be captured in solution from the starting non-enriched genomic library using capture probes, leaving behind the larger population of molecules 50 that contain inserts 10 with non-target sequences.
  • the non-enriched starting genomic DNA library 630 which is used in the first round of target capture, typically contains very few target sequences 10 in comparison to non-target sequences.
  • the capture oligo probes are typically present in a molar excess in the first and second rounds of enrichment.
  • An optional third round of enrichment may also be carried out which contains an excess amount of capture oligo probes that is reduced about 10- fold from the amount of capture oligo probes used in the second round of enrichment.
  • a third round of enrichment may be carried out with a limiting amount of capture probe in order to normalize the content of the library (data not shown).
  • the libraries containing nucleic acid molecules with inserts containing target sequences of interest were generated as described above in Example 2, starting with genomic DNA, DNase I treating, blunt end polishing, and ligating on stem-loop linkers
  • a set of sense and antisense biotinylated capture oligos were generated that target the exons in the 5-gene set- AKTl, BCRAS, PIK3CA, PTEN, and TP53-as shown below in TABLE 8.
  • two sense oligos were synthesized.
  • alternating targeting oligos evenly spaced on opposite strands were chosen.
  • regions longer than 200 nt referred to as "200+”
  • alternating targeting oligos spaced at intervals of about 45 nt to 65 nt were chosen.
  • the oligos were synthesized by Operon and provided at a concentration of 100 ⁇ M.
  • the biotinylated oligos were pooled for subsequent validation of the solution-based capture methodology.
  • InVitrogen's Dynabeads MyOne ® Streptavidin Cl magnetic beads (InVitrogen #650-01) were used (which have a binding capacity of ⁇ 50 pmol of biotinylated dsDNA/50 ⁇ l beads). 120 ⁇ l beads were combined with 500 ⁇ l 2X binding buffer (20 mM Tris pH 7.6, 0.2 niM EDTA, 2M NaCl) and 380 ⁇ l water. The beads were pulled with a magnet and washed twice with 1 ml of IX binding buffer and resuspended in 1200 ⁇ l IX binding buffer.
  • a range of pooled biotinylated target-specific capture oligos was tested at the following concentrations (10 pmol, 1 pmol, 100 attomol, 10 attomol, 1 attomol, no oligo control).
  • a dilution series was set up as follows.
  • a first reaction mixture was prepared with 222 ⁇ l (10 ⁇ g) of PCR product (genomic library), 277.5 ⁇ l of 2X binding buffer (20 mM Tris pH 7.6, 0.2 mM EDTA, 2M NaCl), 22.2 ⁇ l of 1 ⁇ M pooled biotinylated oligos (20 pmol) and 33.3 ⁇ l water.
  • Four tubes were prepared with 200 ⁇ l PCR product, 250 ⁇ l 2X binding buffer and 50 ⁇ l water. Serial 10-fold dilutions were then made of 55 ⁇ l of the first reaction mixture with the biotinylated oligo through the series of the 4 non-biotin containing tubes.
  • a control was prepared with 200 ⁇ l PCR product, 250 ⁇ l 2X binding buffer and 50 ⁇ l water.
  • 10 ⁇ l of the 1 ⁇ M pooled capture oligos were combined with 50 ⁇ l of lOO ng/ ⁇ l genomic library (or a pool of genomic libraries containing 625 ng of each of eight genomic libraries ligated to a particular barcode), 125 ⁇ l of 2X binding buffer and 65 ⁇ l water, for a total volume of 250 ⁇ l.
  • reaction mixture was annealed as follows: 94°C for 30 sec
  • the cycler was allowed to come to room temperature.
  • the 250 ⁇ l annealed mixture was combined with 100 ⁇ l washed beads and
  • the beads were resuspended in either IX binding buffer or TEzero and rocked for 5 minutes prior to pull down. This washing process was carried out four times. The washed beads were then eluted by resuspending them in 50 ⁇ l water, heating to 94°C for 30 seconds, then the beads were pulled with a magnet and the supernatant was removed. The elution process was repeated with another 50 ⁇ l of water, giving a total volume of 100 ⁇ l eluate that contained the enriched fragment library.
  • the PCR reaction products were purified over a Qiaquick® column and quantified.
  • PCR products were analyzed by gene specific qPCR assays to determine the specific activity of target fragments in the enriched, amplified libraries.
  • the Tris buffer in TE stabilizes the solution pH and the DNA duplex, but does not have the electrostatic effect of adding a monovalent cation anion such as NaCl.
  • the monovalent cation anion NaCl was observed to have a negative effect on stringency and enrichment.
  • This experimental data indicates that capture oligonucleotide concentrations in the range of 1.0 to 10 pmol are optimal for capture for 5 ⁇ g of input genomic DNA. Given that the capture was performed in 1 ml, this corresponds to a concentration of 500 ng/ml DNA target and 1 nM to 10 nM capture oligo. This data also indicates that low salt wash (TE (10 mM Tris pH 7.6, 0.1 mM EDTA) is a superior wash buffer over a high salt wash (10 mM Tris pH 7.6, 0.1 mM EDTA, 1 M NaCl).
  • TE mM Tris pH 7.6, 0.1 mM EDTA
  • the level of target fragment specific enrichment achieved after one round of capture was in the range of 500- to 900-fold using the low salt buffer wash conditions. This motivated the following experiment in which it was determined whether a second round of capture using the first round material as input could further enrich for target sequences.
  • 250 ⁇ l of annealed mixture was combined with 250 ⁇ l of set 1 beads (washed in low salt) or with 250 ⁇ l of set 2 beads (washed in high salt).
  • the mixture was incubated at room temperature with mixing for 15 minutes.
  • the beads were pulled out with a magnet and washed four times with 500 ⁇ l of TEzero. For each wash step, the beads were resuspended and rocked for 5 minutes prior to pulling down with the magnet.
  • the washed beads were resuspended in 50 ⁇ l water, heated to 94 0 C for 30 seconds, pulled down with a magnet, and the supernatant with the bound DNA was collected. The process was repeated with an additional 50 ⁇ l, for a total eluate volume of 100 ⁇ l.
  • PCR reaction products were purified over a Qiaquick column and quantified. 1 ⁇ l of PCR product was analyzed on a 2% agarose gel.
  • the TaqMan data from the 5 -gene qPCR assay on the above samples was processed as follows.
  • the raw counts (Cts) were converted to raw quantities calculated with the universal formula: 10(loglO(l/2)*Ct+10).
  • results shown in TABLE 11 are the ratios of the values shown in TABLE 10, as described in the first column of the table, in order to show the fold enrichment level.
  • row number 1 is the ratio of high salt annealed once-enriched genomic pool/gDNA, which is a measure of a single round of enrichment from the starting genomic library (non enriched) to the enriched library, showing an average target enrichment level of approximately 500-fold for the 5 genes, which is very good.
  • Row number 2 of TABLE 11 shows an average of about 50,000-fold target enrichment in the high salt annealed, twice-enriched genomic library relative to the starting non-enriched library. This is a surprisingly successful achievement, given that theoretical perfection (3 billion bases human genome/20 kb target), would be an enrichment of 150,000-fold, which is only a factor of 3-6-fold difference. It is also noted that the approximately 50,000-fold enrichment is reasonably uniform across the five genes. Row number 3 of TABLE 11 shows that the second round of enrichment contributes substantially to the overall target enrichment process, contributing 50-fold more purification relative to a single round alone.
  • the first and second rounds of enrichment described above were both carried out with a concentration of 500 ng/ml DNA target and 1 nM to 10 nM capture oligo.
  • a twice-enriched library can optionally be further enriched prior to sequence analysis by subjecting the twice-enriched library to one more round of solution-based capture.
  • the use of another round of biotin capture on the amplified and enriched material serves to eliminate more of the off-target sequences that may have passed through the enrichment process, and may also be used to level or normalize the fragment representation in the library.
  • Washed beads were prepared by combining 10 ⁇ l beads, 125 ⁇ l 2X binding buffer, and 115 ⁇ l water. The beads were pulled over with a magnet, washed twice with 250 ⁇ l IX binding buffer, and resuspended in 250 ⁇ l IX binding buffer. The annealed 250 ⁇ l mixture was combined with the 250 ⁇ l washed beads, mixed for 15 minutes, the beads were pulled over with a magnet, and the supernatant was decanted. The beads were then washed 4 times with TEzero (low salt).
  • This example describes solution-based capture using indirect capture via chimeric capture oligos with a gene-specific region and a region that hybridizes to a universal biotinylated adaptor oligo, with a set of indirect oligos that are specific for a set of 5 genes of interest.
  • biotinylated gene sequence specific oligonucleotides As demonstrated above in Example 3, the method of targeted sequence capture using biotinylated gene sequence specific oligonucleotides works well for its intended purpose of generating a sequencing library.
  • the drawbacks to the use of biotinylated gene sequence specific oligonucleotides are that biotinylated oligos are expensive reagents to produce, they require a long time to synthesize, and the yields of oligonucleotides are generally low and unpredictably variable.
  • An alternative approach is to use chimeric capture oligonucleotides where one portion of the capture oligonucleotides hybridizes to target sequences and one portion hybridizes to a common, biotinylated oligonucleotide, as shown in FIGURE 5.
  • the chimeric capture oligonucleotides that are not biotinyated are straightforward to produce and the universal (i.e., common) biotinylated oligo is easily manufactured in a single large batch.
  • the advantage of the indirect capture approach is that only a single biotinylated oligonucleotide sequence needs to be synthesized, and the chimeric oligos are pure DNA oligos that are relatively inexpensive to synthesize.
  • an alternative approach for target gene enrichment of a genomic library is to use indirect capture by generating a chimeric capture probe 200, 200' with a first region 202 that hybridizes to a target nucleic acid sequence 10, 10' in the library and a second region 204 that hybridizes to a universal biotinylated oligo 300, mixing the chimeric oligo, the universal biotinylated oligo and the library containing a plurality of nucleic acid molecules 50 under hybridizing conditions to form a tri-molecular complex (i.e., 50/200/300), and using magnetic beads 400 coated with streptavidin 410 to bind to the biotinylated region 310 of the universal oligo 300 and pull out the target sequences 50 bound in the complex to the chimeric capture probe 200, using a magnet 400.
  • a tri-molecular complex i.e., 50/200/300
  • This experiment compares library enrichment using biotinylated capture oligos 100 for direct capture versus chimeric capture oligos 200 that have a first region that hybridizes to a target sequence and a second region that hybridizes to a universal biotinylated oligo.
  • PIK3CA, PTEN, and TP53 which were not biotinylated and that have a first 5' region with the identical sequence to the oligos shown above in TABLE 8, and a second 3' region consisting of the following additional sequence that hybridizes to universal oligo: 5' ACGCGTGGCGGATGTGGACCCCTTCGAGCAATTA 3' (SEQ ID NO:233)
  • a set of exemplary chimeric capture oligos is provided below in TABLE 12 that target AKTl, KRAS, PIK3CA, PTEN, and TP53 that contain a 5' first region (35 nt) that contains sequence that hybridizes to the target gene AKTl, and a 3' region (SEQ ID NO:232) (34 nt) that hybridizes to the universal biotinylated capture oligo (SEQ ID NO:233).
  • a 100 ⁇ M pool was created of all the direct capture oligos (50-mers) (SEQ ID NOS: 111-231), referred to as "D oligo pool.”
  • a 100 ⁇ M pool was created of all the indirect capture chimeric oligos (69-mers), (SEQ ID NOS:234-354) referred to as the "I oligo pool.”
  • 1 ⁇ M of the biotinylated adaptor capture oligo (SEQ ID NO:232) was added to the I oligo pool, referred to as "I oligo pool + capture adaptor oligo.”
  • the above dilution series was prepared as follows: A 1800 ⁇ l master mix was prepared by combining 36 ⁇ g (545 ⁇ l of 66 ng/ ⁇ l pool) of a gDNA library (non-enriched), prepared with heterologous stem loop adaptors as described in Example 2, 900 ⁇ l 2X binding buffer, and 355 ⁇ l water. Aliquots were taken from the master mix with two tubes of 300 ⁇ l and four tubes of 270 ⁇ l.
  • reaction mixtures were annealed as follows:
  • Washed beads were prepared by combining 66 ⁇ l beads, 500 ⁇ l 2X binding buffer and 440 ⁇ l water. The beads were pulled over with a magnet and washed twice with 1 ml IX binding buffer, and resuspended in 600 ⁇ l IX binding buffer. 100 ⁇ l washed beads were transferred to individual tubes and 150 ⁇ l IX binding buffer (10 mM Tris pH 7.6,
  • the DNA bound to the beads was eluted with two aliquots of 50 ⁇ l of water by incubation at 94°C for 30 seconds, pulling over the beads and removing the eluate, for a total eluate volume of 100 ⁇ l.
  • PCR reaction products were purified over a Qiaquick column and quantified. 1 ⁇ l of PCR product was analyzed on a 2% agarose gel.
  • the annealed mixture was then mixed with 10 ⁇ l of washed beads, as described supra.
  • the captured DNA was eluted by resuspending the beads in water, as described supra, to give a total volume of eluate of 100 ⁇ l (twice-enriched).
  • 10 ⁇ l of the eluate was amplified in a 100 ⁇ l PCR reaction under the same conditions shown above, and purified over a Qiaquick ® column.
  • FIGURE 7 A representative alignment to the PIK3CA gene is shown in FIGURE 7.
  • the upper part of FIGURE 7 is a graph showing number of sequencing reads (y-axis) that map to each base of the PIK3CA gene (displayed along the X-axis).
  • the lower portion of FIGURE 7 shows the exon structure for PIK3CA, with solid boxes representing each coding exon that is spliced into the PIK3CA mRNA.
  • all of the targeted exons in the PIK3CA gene (as well as the other targeted exons in the other 4 genes, not shown) showed a read density of > 1000 reads at each targeted exonic base position.
  • This example describes solution-based indirect capture using a population of 3,229 chimeric capture oligos having a first region that is substantially complementary to the sequence of an exon region of one of 77 target genes and a second region for binding to a universal biotinylated oligo, which in turn binds to a capture reagent.
  • This example describes a scale-up from 5 gene targets, 56 exons and 13,267 bp of target sequences that were targeted with 121 oligonucleotides (as described in Example 4), to 77 genes, 1,221 exons, and 304,161 bp of target sequences targeted with 3,229 capture probes.
  • the magnitude of target enrichment was substantially enhanced by more stringent washing of the trimolecular capture complex.
  • a set of 77 genes was identified that is important in the PI3K kinase pathway, shown below in TABLE 16. All the exons of this set of 77 genes were identified, for a total of 1,221 exons, including alternatively spliced exons, for a total target region of 182,061 bases.
  • capture oligonucleotides were chosen as follows. For exons less than 69 nucleotides in length, 2 oligonucleotides, both targeting the same strand and oriented in the same direction and not overlapping one another in sequence by more than 10 nucleotides, were chosen. In some cases where exons were very short (i.e., ⁇ 60 nucleotides), these capture oligonucleotides included flanking exon sequences.
  • oligonucleotides targeting opposite Watson and Crick strands and oriented in the opposite orientations were selected.
  • the first oligonucleotide covered exon base positions 1-35 and the second oligonucleotide was positioned from base positions 80-115, which often included flanking intron sequences so that the oligos were each about 35 nt in length and spaced about 45 nt apart.
  • the first capture oligonucleotide was placed at exon positions 1-35 and successive oligos were placed in alternating orientations with a spacing of 45 nucleotides between oligonucleotides.
  • capture oligonucleotides could be spaced at many different intervals, have many different lengths, and the placement process could take into account genomic features such as genetic variation, G:C content, predicted oligo Tm, and the like.
  • the oligos designed as described above were synthesized by Operon and provided in a plate at 100 ⁇ M and pooled into a single 50 ml sample using a Biomek robot. The pooled 3,229 capture oligos were then diluted to 10 ⁇ M and 1 ⁇ M.
  • TaqMan assays were developed for the 10 genes (AKTl, BRAF, CTNNBl,
  • TaqMan assays were also developed for off-target genes ANKHD and MKRNl for use as negative controls. These genes were not targeted by capture oligonucleotides and it was shown that their representation diminished during the course of target library enrichment.
  • Genomic DNA libraries were generated as described above with a 1/100 DNase I treated library (smaller size distribution) and a 1/200 DNase I treated library (larger insert size distribution), forward stem loop adaptors (SEQ ID NO: 105) and reverse stem loop adaptors (SEQ ID NO:7) were ligated onto the inserts, followed by PCR amplification for 20 cycles with PCR forward primer (SEQ ID NO: 109) and PCR reverse primer (SEQ ID NO: 110), then the PCR product was purified over a Qiaquick column.
  • the reaction mixture was annealed as follows: 94°C for 1 minute
  • Capture Reagents Washed beads were prepared by combining 6 aliquots of 50 ⁇ l beads (in principle, each 50 ⁇ l of beads is capable of binding 50 pmol of dsDNA complex), 500 ⁇ l 2X binding buffer and 440 ⁇ l water. The beads were pulled over with a magnet and washed twice with 1 ml IX binding buffer.
  • wash buffers with increasing formamide were tested, each with 10O mM Tris pH 7.6, 1 niM EDTA, and a range of formamide from 15%, 20%, 25%, 30%, and 50%.
  • the capture oligos/library/bead complexes were washed 4 times with the above-described wash buffers including formamide, 1 ml each wash for 5 minutes.
  • the DNA bound to the beads was eluted with 2 aliquots of 50 ⁇ l of water by incubation at 94 0 C for 1 minute each, pulling over the beads and removing the eluate, for a total eluate volume of 100 ⁇ l. Amplification of Eluate
  • the eluted material was amplified through 20 cycles of PCR as described in Example 5.
  • the DNA bound to the beads was eluted with two aliquots of 50 ⁇ l of water by incubation at 94°C for 1 minute each, pulling over the beads and removing the eluate, for a total eluate volume of 100 ⁇ l.
  • the eluted twice-enriched material was then PCR amplified through 20 cycles using the PCR conditions described above for the once- enriched eluate.
  • the amount of beads was reduced to 5 ⁇ l (instead of 50 ⁇ l in the first and second round of capture) in order to provide just enough beads to bind all complexes present, in order to minimize any non-specific binding effects that may occur with the use of excess beads in the third round of capture.
  • the starting gDNA library, once-enriched and twice-enriched libraries were analyzed by qPCR and submitted for sequence analysis.
  • the qPCR results which monitored 1 exon, each within 10 target genes (out of 1,221 total targeted exons: AKTl, BRAF, CTNNBl, EGFR, KRAS, PIK3CA, PRET, PTEN, TP53, and YWHAH) and 1 exon, each within 2 non-targeted genes (ANKHD and MKRNl) are shown in TABLE 18.
  • shorter insert (100+) and longer insert (200+) libraries of control reference human genomic DNA were captured.
  • TABLE 19 shows the fold enrichment for each individual gene and the averages for all 10 target genes.
  • a sequencing flow cell was created as shown in TABLE 20 in order to determine the specific coverage of target genes as a function of library enrichment and normalization.
  • the 100+ twice-enriched processed library was applied to one lane of an Illumina sequencing flow cell.
  • FIGURE 8 shows the exon structure for AKTl, with solid boxes representing exons and dotted lines representing intron regions.
  • the base-by-base sequencing read depth is plotted on a scale from 0 to 20 reads. As shown in FIGURE 8, each exon region was covered by a sequencing read depth of at least 20 reads, while the intronic regions that were sequenced all clustered around the exonic targets of interest.
  • FIGURE 9 shows the overall characteristics of this data, with the X-axis showing the sequencing coverage depth, defined as the number of times each individual base was found in an aligned sequence.
  • the y-axis shows the percentage of bases, defined as the percentage of bases that have > the coverage depth shown on the x-axis.
  • the percent of target bases was plotted as a function of sequence coverage depth (i.e., number of sequencing reads).
  • the line plotted in FIGURE 9 shows that 99% of the target bases were covered by at least one sequencing read and the arrow shows that 90% of the target bases were covered by 16 or more sequencing reads.
  • This result is important because sequencing read depths >16 are necessary to reveal single nucleotide polymorphisms (SNPs) with confidence. Therefore, this overall coverage analysis indicated that the data obtained from one flow cell lane on a given sample (-4,000,000 reads), there would be adequate sequence coverage depth to determine the presence of a small nucleotide polymorphism (SNP) with confidence across >90% of the target capture region.
  • an additional criterion for the selection of capture probe sequences will be to scan the candidate capture probe sequences for the presence of any known duplicated regions and eliminate these from use.
  • Another approach will be to design the capture probes to selectively align to a particular genomic region of interest, such as a region less than one megabase of the human genome.
  • the concept was to generate low coverage shotgun sequencing of total genomic libraries that contained the number of target regions that were representative of the starting sample and sequencing the library. Read density maps were then generated by mapping the sequencing reads back to large, 500 Kb intervals of a reference genome corresponding to the type of sample. This example describes the application of this method to chromosome 14 of a human subject.
  • a sequencing-ready library of total genomic DNA inserts was generated as described in Example 2, starting with genomic DNA isolated from a healthy human subject, DNase I treating, blunt end polishing, and ligating on stem-loop linkers (SEQ ID NO: 105 and SEQ ID NO: 107), followed by 20 cycles of PCR and purification over a Qiaquick ® column. Analysis
  • Read density maps were generated by mapping the sequencing reads of the once-enriched library back to large, 500 Kb intervals of the sequenced 87.3 Mb portion of human chromosome 14.
  • FIGURE 1OA illustrates the measurement of copy number variation using low-coverage genomic sequencing and molecular karyotyping, with the density of aligning sequencing reads per 100 Kb plotted along the x-axis as the apparent copy number.
  • FIGURE 1OA shows a sample containing a normal diploid chromosomal region (shown on the left), which exhibits a uniform 2 n density of sequencing reads across the entire region.
  • a sample containing 1 normal chromosome and 1 chromosome with a deletion and a tandem duplication shown on the right
  • FIGURE 1OB shows the actual molecular karyotype across the 87.3 Mb sequenced portion of chromosome 14 showing uniform 2 n coverage from the normal human subject using the methods described in this Example. The density of aligning reads per 100 Kb region is plotted on the line shown.
  • This example describes a combination of whole transcriptome amplification, sequencing-ready library generation of the amplified whole transcriptome, enrichment of the library for target sequences of interest, and targeted resequencing of the library.
  • FIGURE HA which contains two SNPs (shown as SNPA and SNPB) associated with cardiovascular risk.
  • the method involves using a population of oligonucleotides to prime the amplification of a target population of nucleic acid molecules within a larger population of nucleic acid molecules, wherein each oligonucleotide comprises a hybridizing portion, wherein the hybridizing portion consists of one of 6, 7, or 8 nucleotides; and the population of oligonucleotides is selected to hybridize under defined conditions to a first subpopulation of the target nucleic acid population (i.e., mRNA molecules obtained from a human subject), but not hybridize under the defined conditions to a second subpopulation of the target nucleic acid population (i.e., ribosomal RNA).
  • a first subpopulation of the target nucleic acid population i.e., mRNA molecules obtained from a human subject
  • a second subpopulation of the target nucleic acid population i.e., ribosomal RNA
  • RNA was extracted from a human subject and reverse transcriptase was used for first strand cDNA synthesis from the template RNA with the set of non-so-random primers. Second strand cDNA synthesis was then carried out and the double-stranded cDNA was used as the starting material for preparation of a sequencing-ready library, as described in Example 2.
  • the chimeric oligos were not biotinylated and each has a first 5' region that hybridizes to the target region of chromosome 9p21, and a second 3' region consisting of the following additional sequence that hybridizes to universal oligo: 5' ACGCGTGGCGGATGTGGACCCCTTCGAGCAATTA 3' (SEQ ID NO:233)
  • This example describes the use of the solution-based capture method for sequence analysis of genomic DNA isolated from clinical patient samples in order to identify genetic markers prognostic for treatment outcomes.
  • Nucleic acids are isolated (DNA or RNA) from clinical samples obtained from subjects undergoing a particular treatment, or from a group of subjects exhibiting a particular phenotype of interest. Sequencing-ready libraries are made from the isolated nucleic acids, and the libraries are then enriched for a particular target region of interest.
  • a target region of interest may encompass the region surrounding a known SNP, such as common SNP "A" that is weakly associated with a rare and unfavorable adverse event.
  • Targeted resequencing of a ⁇ 40 Kb region surrounding this SNP uncovers a rare C — »T SNP that is more strongly associated with the adverse event. Genotyping for the rare T variant in treatment populations would enable clinicians to eliminate subjects vulnerable to unfavorable outcomes.
  • the methods described in this example may be carried out on a plurality of nucleic acid-containing samples obtained over a period of time from the human subject in order to monitor the subject for genetic mutations in a target region of interest or to monitor the effect of a particular treatment regimen on a subject.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions et des procédés de génération d'une bibliothèque prête à séquencer, enrichie en cibles, destinée à séquencer de nouveau au moins une région cible intéressante à partir d'un échantillon contenant un acide nucléique.
EP09813548A 2008-09-09 2009-09-09 Procédés de génération de bibliothèques spécifiques de gènes Withdrawn EP2334802A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9557908P 2008-09-09 2008-09-09
PCT/US2009/056380 WO2010030683A1 (fr) 2008-09-09 2009-09-09 Procédés de génération de bibliothèques spécifiques de gènes

Publications (2)

Publication Number Publication Date
EP2334802A1 true EP2334802A1 (fr) 2011-06-22
EP2334802A4 EP2334802A4 (fr) 2012-01-25

Family

ID=42005453

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09813548A Withdrawn EP2334802A4 (fr) 2008-09-09 2009-09-09 Procédés de génération de bibliothèques spécifiques de gènes

Country Status (3)

Country Link
EP (1) EP2334802A4 (fr)
CN (1) CN102203273A (fr)
WO (1) WO2010030683A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9618474B2 (en) 2014-12-18 2017-04-11 Edico Genome, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
US9857328B2 (en) 2014-12-18 2018-01-02 Agilome, Inc. Chemically-sensitive field effect transistors, systems and methods for manufacturing and using the same
US9859394B2 (en) 2014-12-18 2018-01-02 Agilome, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
US10006910B2 (en) 2014-12-18 2018-06-26 Agilome, Inc. Chemically-sensitive field effect transistors, systems, and methods for manufacturing and using the same
US10020300B2 (en) 2014-12-18 2018-07-10 Agilome, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
US10429342B2 (en) 2014-12-18 2019-10-01 Edico Genome Corporation Chemically-sensitive field effect transistor
US10811539B2 (en) 2016-05-16 2020-10-20 Nanomedical Diagnostics, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2750879C (fr) 2009-01-30 2018-05-22 Oxford Nanopore Technologies Limited Adaptateurs pour des constructions d'acide nucleique dans le sequencage de sequences transmembranaires
US20110319290A1 (en) * 2010-06-08 2011-12-29 Nugen Technologies, Inc. Methods and Compositions for Multiplex Sequencing
CN102409043B (zh) * 2010-09-21 2013-12-04 深圳华大基因科技服务有限公司 高通量低成本Fosmid文库构建的方法及其所使用标签和标签接头
CN102409408B (zh) * 2010-09-21 2013-08-07 深圳华大基因科技服务有限公司 一种利用微量基因组dna进行全基因组甲基化位点精确检测的方法
WO2013075313A1 (fr) * 2011-11-24 2013-05-30 深圳华大基因科技有限公司 Sonde de détection du mode d'intégration d'un virus dans un échantillon d'essai et procédé de préparation et d'utilisation associé
WO2012175013A1 (fr) * 2011-06-24 2012-12-27 深圳华大基因科技有限公司 Système et méthode de diagnostic d'un corps humain ayant un état anormal
KR20140050067A (ko) * 2011-07-25 2014-04-28 옥스포드 나노포어 테크놀로지즈 리미티드 막횡단 포어를 사용한 이중 가닥 폴리뉴클레오티드 서열분석을 위한 헤어핀 루프 방법
GB2497838A (en) 2011-10-19 2013-06-26 Nugen Technologies Inc Compositions and methods for directional nucleic acid amplification and sequencing
EP4372084A3 (fr) 2012-01-26 2024-08-14 Tecan Genomics, Inc. Compositions et procédés pour l'enrichissement ciblé de séquences d'acides nucléiques et la génération de bibliothèques à haute efficacité
CN104619894B (zh) 2012-06-18 2017-06-06 纽亘技术公司 用于非期望核酸序列的阴性选择的组合物和方法
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
CN104903466B (zh) * 2012-11-05 2016-11-23 鲁比康基因组学公司 条形编码核酸
CN105209634B (zh) 2013-03-08 2020-05-12 牛津纳米孔技术公司 酶停滞方法
US20140274738A1 (en) 2013-03-15 2014-09-18 Nugen Technologies, Inc. Sequential sequencing
CA2929596C (fr) 2013-11-13 2022-07-05 Nugen Technologies, Inc. Compositions et procedes pour l'identification d'une lecture de sequencage en double
CN110819621B (zh) * 2014-02-11 2024-03-26 豪夫迈·罗氏有限公司 靶向测序和uid过滤
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
WO2015131107A1 (fr) 2014-02-28 2015-09-03 Nugen Technologies, Inc. Séquençage au bisulfite de représentation réduite avec adaptateurs de diversité
CA2953362A1 (fr) * 2014-06-23 2015-12-30 The General Hospital Corporation Identification non biaisee, pangenomique, de dsb evaluee par sequencage (guide-seq)
JP6803327B2 (ja) 2014-08-06 2020-12-23 ニューゲン テクノロジーズ， インコーポレイテッド 標的化されたシークエンシングからのデジタル測定値
ES2726149T3 (es) * 2014-09-12 2019-10-02 Mgi Tech Co Ltd Oligonucleótido aislado y su uso en la secuenciación de ácidos nucleicos
US10704084B2 (en) * 2014-12-02 2020-07-07 Tribiotica Llc Methods and kits for theranostic applications
US10640752B2 (en) * 2014-12-22 2020-05-05 Veterinærinstituttet Salmon gill poxvirus
CN104946639B (zh) * 2015-07-01 2017-10-31 益善生物技术股份有限公司 构建基因突变测序文库的引物和方法以及试剂盒
WO2017117440A1 (fr) * 2015-12-30 2017-07-06 Bio-Rad Laboratories, Inc. Préparation de banque de pcr séparée en gouttelettes
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
JP6860662B2 (ja) * 2016-10-31 2021-04-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ キメラ生成物の同定のためのバーコードを付けられた環状ライブラリーの構築
US20180142289A1 (en) * 2016-11-18 2018-05-24 Twist Bioscience Corporation Polynucleotide libraries having controlled stoichiometry and synthesis thereof
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
CN109750092B (zh) 2017-11-03 2022-12-06 北京贝瑞和康生物技术有限公司 一种靶向富集高gc含量目标dna的方法和试剂盒
CN108004301B (zh) * 2017-12-15 2022-02-22 格诺思博生物科技南通有限公司 基因目标区域富集方法及建库试剂盒
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
CN115103909A (zh) * 2020-01-31 2022-09-23 艾维达生物医学公司 用于靶向核酸捕获的系统和方法
US12059674B2 (en) 2020-02-03 2024-08-13 Tecan Genomics, Inc. Reagent storage system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1184466A2 (fr) * 2000-08-26 2002-03-06 Affymetrix, Inc. Enrichissiment et amplification des cibles d'acide nucleique pour l'analyse dans un réseau
WO2002083943A2 (fr) * 2001-04-12 2002-10-24 Epigenomics Ag Procede a microreseau permettant d'enrichir des fragments d'adn provenant de melanges complexes
WO2007057652A1 (fr) * 2005-11-15 2007-05-24 Solexa Limited Methode d'enrichissement de cible

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681726A (en) * 1988-09-19 1997-10-28 Stratagene Method of double stranded DNA synthesis
US6924104B2 (en) * 2000-10-27 2005-08-02 Yale University Methods for identifying genes associated with diseases or specific phenotypes
GB0114853D0 (en) * 2001-06-18 2001-08-08 Medical Res Council Happier Mapping
WO2004009796A2 (fr) * 2002-07-24 2004-01-29 Immusol Incorporated Systeme a un seul promoteur pour la production de cassettes d'expression d'arnsi et genotheque d'expression reposant sur l'utilisation d'un lieur en epingle a cheveux d'amorce de polymerase
US20060051789A1 (en) * 2004-07-01 2006-03-09 Somagenics, Inc. Methods of preparation of gene-specific oligonucleotide libraries and uses thereof
ATE510930T1 (de) * 2005-08-02 2011-06-15 Rubicon Genomics Inc Zusammensetzungen und verfahren zur bearbeitung und amplifikation von dna mit verwendung mehrerer enzyme in einer einzigen reaktion

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1184466A2 (fr) * 2000-08-26 2002-03-06 Affymetrix, Inc. Enrichissiment et amplification des cibles d'acide nucleique pour l'analyse dans un réseau
WO2002083943A2 (fr) * 2001-04-12 2002-10-24 Epigenomics Ag Procede a microreseau permettant d'enrichir des fragments d'adn provenant de melanges complexes
WO2007057652A1 (fr) * 2005-11-15 2007-05-24 Solexa Limited Methode d'enrichissement de cible

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JUDY ST. JOHN ET AL: "Rapid capture of DNA targets", BIOTECHNIQUES, vol. 44, no. 2, 1 February 2008 (2008-02-01), pages 259-264, XP55014746, ISSN: 0736-6205, DOI: 10.2144/000112633 *
OKOU DAVID T ET AL: "Microarray-based genomic selection for high-throughput resequencing", NATURE METHODS, NATURE PUBLISHING GROUP, GB, vol. 4, no. 11, 1 October 2007 (2007-10-01), pages 907-909, XP002528498, ISSN: 1548-7091, DOI: 10.1038/NMETH1109 *
See also references of WO2010030683A1 *
UNN HILDE REFSETH ET AL: "HYBRIDIZATION CAPTURE OF MICROSATELLITES DIRECTLY FROM GENOMIC DNA", ELECTROPHORESIS, WILEY INTERSCIENCE, DE, vol. 18, no. 9, 1 January 1997 (1997-01-01), pages 1519-1523, XP002952426, ISSN: 0173-0835, DOI: 10.1002/ELPS.1150180905 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9618474B2 (en) 2014-12-18 2017-04-11 Edico Genome, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
US9857328B2 (en) 2014-12-18 2018-01-02 Agilome, Inc. Chemically-sensitive field effect transistors, systems and methods for manufacturing and using the same
US9859394B2 (en) 2014-12-18 2018-01-02 Agilome, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
US10006910B2 (en) 2014-12-18 2018-06-26 Agilome, Inc. Chemically-sensitive field effect transistors, systems, and methods for manufacturing and using the same
US10020300B2 (en) 2014-12-18 2018-07-10 Agilome, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
US10429381B2 (en) 2014-12-18 2019-10-01 Agilome, Inc. Chemically-sensitive field effect transistors, systems, and methods for manufacturing and using the same
US10429342B2 (en) 2014-12-18 2019-10-01 Edico Genome Corporation Chemically-sensitive field effect transistor
US10494670B2 (en) 2014-12-18 2019-12-03 Agilome, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
US10607989B2 (en) 2014-12-18 2020-03-31 Nanomedical Diagnostics, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
US10811539B2 (en) 2016-05-16 2020-10-20 Nanomedical Diagnostics, Inc. Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids

Also Published As

Publication number Publication date
EP2334802A4 (fr) 2012-01-25
CN102203273A (zh) 2011-09-28
WO2010030683A1 (fr) 2010-03-18

Similar Documents

Publication Publication Date Title
EP2334802A1 (fr) Procédés de génération de bibliothèques spécifiques de gènes
US11999949B2 (en) Methods for targeted genomic analysis
US20120015821A1 (en) Methods of Generating Gene Specific Libraries
US8986958B2 (en) Methods for generating target specific probes for solution based capture
JP7008407B2 (ja) ヌクレアーゼ、リガーゼ、ポリメラーゼ、及び配列決定反応の組み合わせを用いた、核酸配列、発現、コピー、またはｄｎａのメチル化変化の識別及び計数方法
JP6982087B2 (ja) 競合的鎖置換を利用する次世代シーケンシング（ｎｇｓ）ライブラリーの構築
US9790543B2 (en) Methods and systems for solution based sequence enrichment
EP2880182B1 (fr) Enrichissement d'adn ciblé médié par la recombinase pour le séquençage de prochaine génération
EP1954818B2 (fr) Procede pour preparer des bibliotheques de polynucleotides matrices
US20100222232A1 (en) Enrichment and sequence analysis of genomic regions
AU2015364286A1 (en) Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using CRISPR/Cas system proteins
EP2494069B1 (fr) Procédé de détection des aberrations chromosomiques équilibrées
WO2013192292A1 (fr) Analyse de séquence d'acide nucléique spécifique d'un locus multiplexe massivement parallèle
JP2023513606A (ja) 核酸を評価するための方法および材料
US20140336058A1 (en) Method and kit for characterizing rna in a composition
KR20140119602A (ko) 염기 특이 반응성 프라이머를 이용한 핵산 증폭방법
KR20230124636A (ko) 멀티플렉스 반응에서 표적 서열의 고 감응성 검출을위한 조성물 및 방법
WO2010064040A1 (fr) Procédé pour séquençage de polynucléotides
WO2024137703A1 (fr) Ensembles multivalents pour une hybridation de cible améliorée

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110408

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20111223

RIC1 Information provided on ipc code assigned before grant

Ipc: C40B 50/06 20060101ALI20111219BHEP

Ipc: C40B 40/08 20060101ALI20111219BHEP

Ipc: C40B 40/06 20060101ALI20111219BHEP

Ipc: C12N 15/10 20060101ALI20111219BHEP

Ipc: C12N 15/66 20060101ALI20111219BHEP

Ipc: C12Q 1/68 20060101AFI20111219BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20120703